# PeptideScanner evidence objects: Triptorelin

Every published version of the records placed with Triptorelin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/triptorelin.json. Selected public evidence only; not medical advice.

- Objects: 67
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00003026-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT00003026

> PeptideScanner retained ClinicalTrials.gov record NCT00003026 at 2026-11-15T21:49:16.513Z. Its registry update date was 2012-07-02, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct00003026-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-07-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00003026-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00003026-triptorelin-v1
- Content SHA-256: `7a06825a85b320c677374ad0d934c7316ebf23403ab583af781a12a7528d793a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00003026 ([`ctg-observation-nct00003026-2012-07-02-1f1eeaa09d9d`](#source-ctg-observation-nct00003026-2012-07-02-1f1eeaa09d9d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00003026 at 2026-11-15T21:49:16.513Z. Its registry update date was 2012-07-02, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00003026-2012-07-02-1f1eeaa09d9d`](#source-ctg-observation-nct00003026-2012-07-02-1f1eeaa09d9d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00003026 at 2026-11-15T21:49:16.513Z. Its registry update date was 2012-07-02, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00003026-2012-07-02-1f1eeaa09d9d`](#source-ctg-observation-nct00003026-2012-07-02-1f1eeaa09d9d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00003026-2012-07-02-1f1eeaa09d9d`](#source-ctg-observation-nct00003026-2012-07-02-1f1eeaa09d9d))

### Sources

<a id="source-ctg-observation-nct00003026-2012-07-02-1f1eeaa09d9d"></a>
- **ClinicalTrials.gov record NCT00003026 · retained source version 2012-07-02:1f1eeaa09d9d5fc75fe704919cb0929b578f6716370254fd6ed0557a95a090ac** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00003026) (`ctg-observation-nct00003026-2012-07-02-1f1eeaa09d9d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00003026." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00003026-triptorelin-v1 SHA-256: 7a06825a85b320c677374ad0d934c7316ebf23403ab583af781a12a7528d793a.

---

<a id="clinicaltrials-gov-nct00066690-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT00066690

> PeptideScanner retained ClinicalTrials.gov record NCT00066690 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-26, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct00066690-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00066690-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00066690-triptorelin-v1
- Content SHA-256: `0eeead5ba2795bb716497642a0bbb8fd7aeaedefb7501faa1b61b60c414a8c00`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00066690 ([`ctg-observation-nct00066690-2026-08-26-2dc5bebe075f`](#source-ctg-observation-nct00066690-2026-08-26-2dc5bebe075f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00066690 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-26, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00066690-2026-08-26-2dc5bebe075f`](#source-ctg-observation-nct00066690-2026-08-26-2dc5bebe075f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00066690 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-26, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00066690-2026-08-26-2dc5bebe075f`](#source-ctg-observation-nct00066690-2026-08-26-2dc5bebe075f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00066690-2026-08-26-2dc5bebe075f`](#source-ctg-observation-nct00066690-2026-08-26-2dc5bebe075f))

### Sources

<a id="source-ctg-observation-nct00066690-2026-08-26-2dc5bebe075f"></a>
- **ClinicalTrials.gov record NCT00066690 · retained source version 2026-08-26:2dc5bebe075f3ae84769828500383c4cc5a81c42f64b138d10a59c31e9bc741a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00066690) (`ctg-observation-nct00066690-2026-08-26-2dc5bebe075f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00066690." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00066690-triptorelin-v1 SHA-256: 0eeead5ba2795bb716497642a0bbb8fd7aeaedefb7501faa1b61b60c414a8c00.

---

<a id="clinicaltrials-gov-nct00066703-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT00066703

> PeptideScanner retained ClinicalTrials.gov record NCT00066703 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct00066703-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00066703-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00066703-triptorelin-v1
- Content SHA-256: `4d9ae1be7c4fa3a7283ebcc124236aa30224f310b2caee723aa403c7fc03211b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00066703 ([`ctg-observation-nct00066703-2026-02-06-3bdf66aa4800`](#source-ctg-observation-nct00066703-2026-02-06-3bdf66aa4800))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00066703 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00066703-2026-02-06-3bdf66aa4800`](#source-ctg-observation-nct00066703-2026-02-06-3bdf66aa4800))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00066703 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00066703-2026-02-06-3bdf66aa4800`](#source-ctg-observation-nct00066703-2026-02-06-3bdf66aa4800))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00066703-2026-02-06-3bdf66aa4800`](#source-ctg-observation-nct00066703-2026-02-06-3bdf66aa4800))

### Sources

<a id="source-ctg-observation-nct00066703-2026-02-06-3bdf66aa4800"></a>
- **ClinicalTrials.gov record NCT00066703 · retained source version 2026-02-06:3bdf66aa4800ec2d87826fc2ee3bac78ef7f2c6cab90d7f0652e3e0cc7f86b9d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00066703) (`ctg-observation-nct00066703-2026-02-06-3bdf66aa4800`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00066703." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00066703-triptorelin-v1 SHA-256: 4d9ae1be7c4fa3a7283ebcc124236aa30224f310b2caee723aa403c7fc03211b.

---

<a id="clinicaltrials-gov-nct00104741-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT00104741

> PeptideScanner retained ClinicalTrials.gov record NCT00104741 at 2026-11-15T21:49:16.513Z. Its registry update date was 2021-02-21, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct00104741-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-02-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00104741-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00104741-triptorelin-v1
- Content SHA-256: `7175e36cedbb2ff4e970a3f41ce7b139f008781f772c8805e0ddc9ac9454567c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00104741 ([`ctg-observation-nct00104741-2021-02-21-0cdab8b8cd8e`](#source-ctg-observation-nct00104741-2021-02-21-0cdab8b8cd8e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00104741 at 2026-11-15T21:49:16.513Z. Its registry update date was 2021-02-21, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00104741-2021-02-21-0cdab8b8cd8e`](#source-ctg-observation-nct00104741-2021-02-21-0cdab8b8cd8e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00104741 at 2026-11-15T21:49:16.513Z. Its registry update date was 2021-02-21, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00104741-2021-02-21-0cdab8b8cd8e`](#source-ctg-observation-nct00104741-2021-02-21-0cdab8b8cd8e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00104741-2021-02-21-0cdab8b8cd8e`](#source-ctg-observation-nct00104741-2021-02-21-0cdab8b8cd8e))

### Sources

<a id="source-ctg-observation-nct00104741-2021-02-21-0cdab8b8cd8e"></a>
- **ClinicalTrials.gov record NCT00104741 · retained source version 2021-02-21:0cdab8b8cd8e8a1c8b4d5e31c3e5e8d93f4059fc45a3faf2c08f62381be86cae** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00104741) (`ctg-observation-nct00104741-2021-02-21-0cdab8b8cd8e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00104741." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00104741-triptorelin-v1 SHA-256: 7175e36cedbb2ff4e970a3f41ce7b139f008781f772c8805e0ddc9ac9454567c.

---

<a id="clinicaltrials-gov-nct00311636-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT00311636

> PeptideScanner retained ClinicalTrials.gov record NCT00311636 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-06-26, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct00311636-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-06-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00311636-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00311636-triptorelin-v1
- Content SHA-256: `670e8d3a612abc2c991680430ac6f3a50d8fb5cbd55e7e2a6c3a897c2ef7a50d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00311636 ([`ctg-observation-nct00311636-2013-06-26-b4f1cc3efa80`](#source-ctg-observation-nct00311636-2013-06-26-b4f1cc3efa80))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00311636 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-06-26, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00311636-2013-06-26-b4f1cc3efa80`](#source-ctg-observation-nct00311636-2013-06-26-b4f1cc3efa80))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00311636 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-06-26, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00311636-2013-06-26-b4f1cc3efa80`](#source-ctg-observation-nct00311636-2013-06-26-b4f1cc3efa80))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00311636-2013-06-26-b4f1cc3efa80`](#source-ctg-observation-nct00311636-2013-06-26-b4f1cc3efa80))

### Sources

<a id="source-ctg-observation-nct00311636-2013-06-26-b4f1cc3efa80"></a>
- **ClinicalTrials.gov record NCT00311636 · retained source version 2013-06-26:b4f1cc3efa80d261824dd6e908da1021fc65f47feb2c49a4953bc0ae06635197** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00311636) (`ctg-observation-nct00311636-2013-06-26-b4f1cc3efa80`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00311636." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00311636-triptorelin-v1 SHA-256: 670e8d3a612abc2c991680430ac6f3a50d8fb5cbd55e7e2a6c3a897c2ef7a50d.

---

<a id="clinicaltrials-gov-nct00659373-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT00659373

> PeptideScanner retained ClinicalTrials.gov record NCT00659373 at 2026-11-15T21:49:16.513Z. Its registry update date was 2016-07-25, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct00659373-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-07-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00659373-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00659373-triptorelin-v1
- Content SHA-256: `22dc14a2ede434b0555f861e2936db58bab586b13acab378d7edd9d3c7db98fe`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00659373 ([`ctg-observation-nct00659373-2016-07-25-dfe103a0a685`](#source-ctg-observation-nct00659373-2016-07-25-dfe103a0a685))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00659373 at 2026-11-15T21:49:16.513Z. Its registry update date was 2016-07-25, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00659373-2016-07-25-dfe103a0a685`](#source-ctg-observation-nct00659373-2016-07-25-dfe103a0a685))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00659373 at 2026-11-15T21:49:16.513Z. Its registry update date was 2016-07-25, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00659373-2016-07-25-dfe103a0a685`](#source-ctg-observation-nct00659373-2016-07-25-dfe103a0a685))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00659373-2016-07-25-dfe103a0a685`](#source-ctg-observation-nct00659373-2016-07-25-dfe103a0a685))

### Sources

<a id="source-ctg-observation-nct00659373-2016-07-25-dfe103a0a685"></a>
- **ClinicalTrials.gov record NCT00659373 · retained source version 2016-07-25:dfe103a0a6855a30e047c02ba3112ea94e82950af302f0865933a08d6f9b2daa** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00659373) (`ctg-observation-nct00659373-2016-07-25-dfe103a0a685`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00659373." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00659373-triptorelin-v1 SHA-256: 22dc14a2ede434b0555f861e2936db58bab586b13acab378d7edd9d3c7db98fe.

---

<a id="clinicaltrials-gov-nct00667069-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT00667069

> PeptideScanner retained ClinicalTrials.gov record NCT00667069 at 2026-11-15T21:49:16.513Z. Its registry update date was 2025-06-05, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct00667069-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-06-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00667069-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00667069-triptorelin-v1
- Content SHA-256: `bdc94de9cc79cc01f106f23e19911066a1dad9592292318ee194e847259ebd79`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00667069 ([`ctg-observation-nct00667069-2025-06-05-77c28ef275aa`](#source-ctg-observation-nct00667069-2025-06-05-77c28ef275aa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00667069 at 2026-11-15T21:49:16.513Z. Its registry update date was 2025-06-05, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00667069-2025-06-05-77c28ef275aa`](#source-ctg-observation-nct00667069-2025-06-05-77c28ef275aa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00667069 at 2026-11-15T21:49:16.513Z. Its registry update date was 2025-06-05, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00667069-2025-06-05-77c28ef275aa`](#source-ctg-observation-nct00667069-2025-06-05-77c28ef275aa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00667069-2025-06-05-77c28ef275aa`](#source-ctg-observation-nct00667069-2025-06-05-77c28ef275aa))

### Sources

<a id="source-ctg-observation-nct00667069-2025-06-05-77c28ef275aa"></a>
- **ClinicalTrials.gov record NCT00667069 · retained source version 2025-06-05:77c28ef275aa7b099f94ea27cc51f8b575d023151aa729c48f8d270db29b2a61** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00667069) (`ctg-observation-nct00667069-2025-06-05-77c28ef275aa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00667069." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00667069-triptorelin-v1 SHA-256: bdc94de9cc79cc01f106f23e19911066a1dad9592292318ee194e847259ebd79.

---

<a id="clinicaltrials-gov-nct00702520-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT00702520

> PeptideScanner retained ClinicalTrials.gov record NCT00702520 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct00702520-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-09-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00702520-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00702520-triptorelin-v1
- Content SHA-256: `a89cd6a1049e1a773a6decaaafed8c6a0659182d6f780ed9169c57d6342fbba0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00702520 ([`ctg-observation-nct00702520-2024-09-05-a1373d4c7f7a`](#source-ctg-observation-nct00702520-2024-09-05-a1373d4c7f7a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00702520 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00702520-2024-09-05-a1373d4c7f7a`](#source-ctg-observation-nct00702520-2024-09-05-a1373d4c7f7a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00702520 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct00702520-2024-09-05-a1373d4c7f7a`](#source-ctg-observation-nct00702520-2024-09-05-a1373d4c7f7a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00702520-2024-09-05-a1373d4c7f7a`](#source-ctg-observation-nct00702520-2024-09-05-a1373d4c7f7a))

### Sources

<a id="source-ctg-observation-nct00702520-2024-09-05-a1373d4c7f7a"></a>
- **ClinicalTrials.gov record NCT00702520 · retained source version 2024-09-05:a1373d4c7f7aa3b155a97bd8864dd7730c9b27ee92ff0dcee084780452440d02** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00702520) (`ctg-observation-nct00702520-2024-09-05-a1373d4c7f7a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00702520." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct00702520-triptorelin-v1 SHA-256: a89cd6a1049e1a773a6decaaafed8c6a0659182d6f780ed9169c57d6342fbba0.

---

<a id="clinicaltrials-gov-nct01160315-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT01160315

> PeptideScanner retained ClinicalTrials.gov record NCT01160315 at 2026-11-15T21:49:16.513Z. Its registry update date was 2015-10-30, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct01160315-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-10-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01160315-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct01160315-triptorelin-v1
- Content SHA-256: `db2ac8bbceaa581f6ee0c24fd874408962d39887eba9c6d2885535e554aa27a0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01160315 ([`ctg-observation-nct01160315-2015-10-30-29f67f11b534`](#source-ctg-observation-nct01160315-2015-10-30-29f67f11b534))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01160315 at 2026-11-15T21:49:16.513Z. Its registry update date was 2015-10-30, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct01160315-2015-10-30-29f67f11b534`](#source-ctg-observation-nct01160315-2015-10-30-29f67f11b534))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01160315 at 2026-11-15T21:49:16.513Z. Its registry update date was 2015-10-30, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct01160315-2015-10-30-29f67f11b534`](#source-ctg-observation-nct01160315-2015-10-30-29f67f11b534))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01160315-2015-10-30-29f67f11b534`](#source-ctg-observation-nct01160315-2015-10-30-29f67f11b534))

### Sources

<a id="source-ctg-observation-nct01160315-2015-10-30-29f67f11b534"></a>
- **ClinicalTrials.gov record NCT01160315 · retained source version 2015-10-30:29f67f11b534514e443ecdb2995d751bec71d5b45f28a595e048685ef7ccd294** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01160315) (`ctg-observation-nct01160315-2015-10-30-29f67f11b534`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01160315." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct01160315-triptorelin-v1 SHA-256: db2ac8bbceaa581f6ee0c24fd874408962d39887eba9c6d2885535e554aa27a0.

---

<a id="clinicaltrials-gov-nct01467882-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT01467882

> PeptideScanner retained ClinicalTrials.gov record NCT01467882 at 2026-11-15T21:49:16.513Z. Its registry update date was 2017-07-28, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct01467882-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-07-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01467882-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct01467882-triptorelin-v1
- Content SHA-256: `81e250db30fe0bab8d1043827e667e5d49840911b52d953df5fac155793b0ade`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01467882 ([`ctg-observation-nct01467882-2017-07-28-c856dae78731`](#source-ctg-observation-nct01467882-2017-07-28-c856dae78731))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01467882 at 2026-11-15T21:49:16.513Z. Its registry update date was 2017-07-28, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct01467882-2017-07-28-c856dae78731`](#source-ctg-observation-nct01467882-2017-07-28-c856dae78731))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01467882 at 2026-11-15T21:49:16.513Z. Its registry update date was 2017-07-28, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct01467882-2017-07-28-c856dae78731`](#source-ctg-observation-nct01467882-2017-07-28-c856dae78731))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01467882-2017-07-28-c856dae78731`](#source-ctg-observation-nct01467882-2017-07-28-c856dae78731))

### Sources

<a id="source-ctg-observation-nct01467882-2017-07-28-c856dae78731"></a>
- **ClinicalTrials.gov record NCT01467882 · retained source version 2017-07-28:c856dae78731d44a7e50c6b6acdc642696afcbc38dc4606af6610d3d3c2f31fa** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01467882) (`ctg-observation-nct01467882-2017-07-28-c856dae78731`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01467882." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct01467882-triptorelin-v1 SHA-256: 81e250db30fe0bab8d1043827e667e5d49840911b52d953df5fac155793b0ade.

---

<a id="clinicaltrials-gov-nct01500863-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT01500863

> PeptideScanner retained ClinicalTrials.gov record NCT01500863 at 2026-11-15T21:49:16.513Z. Its registry update date was 2016-10-26, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct01500863-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-10-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01500863-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct01500863-triptorelin-v1
- Content SHA-256: `60d903e19e2d611d4734f5e1ab1f9148fd9b9ffd2407e44c6db7d03ead278992`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01500863 ([`ctg-observation-nct01500863-2016-10-26-e6b0afbbf2ce`](#source-ctg-observation-nct01500863-2016-10-26-e6b0afbbf2ce))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01500863 at 2026-11-15T21:49:16.513Z. Its registry update date was 2016-10-26, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct01500863-2016-10-26-e6b0afbbf2ce`](#source-ctg-observation-nct01500863-2016-10-26-e6b0afbbf2ce))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01500863 at 2026-11-15T21:49:16.513Z. Its registry update date was 2016-10-26, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct01500863-2016-10-26-e6b0afbbf2ce`](#source-ctg-observation-nct01500863-2016-10-26-e6b0afbbf2ce))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01500863-2016-10-26-e6b0afbbf2ce`](#source-ctg-observation-nct01500863-2016-10-26-e6b0afbbf2ce))

### Sources

<a id="source-ctg-observation-nct01500863-2016-10-26-e6b0afbbf2ce"></a>
- **ClinicalTrials.gov record NCT01500863 · retained source version 2016-10-26:e6b0afbbf2ce6824fd10a57395016a27955bda346811874ac3bb059fcad48398** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01500863) (`ctg-observation-nct01500863-2016-10-26-e6b0afbbf2ce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01500863." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct01500863-triptorelin-v1 SHA-256: 60d903e19e2d611d4734f5e1ab1f9148fd9b9ffd2407e44c6db7d03ead278992.

---

<a id="clinicaltrials-gov-nct01732068-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT01732068

> PeptideScanner retained ClinicalTrials.gov record NCT01732068 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-05-09, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct01732068-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-05-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01732068-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct01732068-triptorelin-v1
- Content SHA-256: `0079312b2619f815798bd3147414e62acfb3b8436a5737154e3e6c8b1a50aae4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01732068 ([`ctg-observation-nct01732068-2013-05-09-d9acb2fa6140`](#source-ctg-observation-nct01732068-2013-05-09-d9acb2fa6140))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01732068 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-05-09, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct01732068-2013-05-09-d9acb2fa6140`](#source-ctg-observation-nct01732068-2013-05-09-d9acb2fa6140))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01732068 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-05-09, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct01732068-2013-05-09-d9acb2fa6140`](#source-ctg-observation-nct01732068-2013-05-09-d9acb2fa6140))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01732068-2013-05-09-d9acb2fa6140`](#source-ctg-observation-nct01732068-2013-05-09-d9acb2fa6140))

### Sources

<a id="source-ctg-observation-nct01732068-2013-05-09-d9acb2fa6140"></a>
- **ClinicalTrials.gov record NCT01732068 · retained source version 2013-05-09:d9acb2fa614062b88643168f2c6cedd581c2c47696341764ca81c7d276b3dc3f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01732068) (`ctg-observation-nct01732068-2013-05-09-d9acb2fa6140`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01732068." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct01732068-triptorelin-v1 SHA-256: 0079312b2619f815798bd3147414e62acfb3b8436a5737154e3e6c8b1a50aae4.

---

<a id="clinicaltrials-gov-nct01732094-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT01732094

> PeptideScanner retained ClinicalTrials.gov record NCT01732094 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-05-09, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct01732094-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-05-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01732094-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct01732094-triptorelin-v1
- Content SHA-256: `520858218a3d3603dc3c4df65cb591290c2396ab1786e0a8f5824caa02b1d360`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01732094 ([`ctg-observation-nct01732094-2013-05-09-c1e8e568e22e`](#source-ctg-observation-nct01732094-2013-05-09-c1e8e568e22e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01732094 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-05-09, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct01732094-2013-05-09-c1e8e568e22e`](#source-ctg-observation-nct01732094-2013-05-09-c1e8e568e22e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01732094 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-05-09, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct01732094-2013-05-09-c1e8e568e22e`](#source-ctg-observation-nct01732094-2013-05-09-c1e8e568e22e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01732094-2013-05-09-c1e8e568e22e`](#source-ctg-observation-nct01732094-2013-05-09-c1e8e568e22e))

### Sources

<a id="source-ctg-observation-nct01732094-2013-05-09-c1e8e568e22e"></a>
- **ClinicalTrials.gov record NCT01732094 · retained source version 2013-05-09:c1e8e568e22e7597935342351e05510f2243313e69712abb02858e5128ef136f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01732094) (`ctg-observation-nct01732094-2013-05-09-c1e8e568e22e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01732094." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct01732094-triptorelin-v1 SHA-256: 520858218a3d3603dc3c4df65cb591290c2396ab1786e0a8f5824caa02b1d360.

---

<a id="clinicaltrials-gov-nct01764230-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT01764230

> PeptideScanner retained ClinicalTrials.gov record NCT01764230 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-01-09, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct01764230-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-01-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01764230-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct01764230-triptorelin-v1
- Content SHA-256: `411edfd1f451966190e08470cf674922ad63826d8a64959e755fe93669477007`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01764230 ([`ctg-observation-nct01764230-2013-01-09-e19225da2081`](#source-ctg-observation-nct01764230-2013-01-09-e19225da2081))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01764230 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-01-09, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct01764230-2013-01-09-e19225da2081`](#source-ctg-observation-nct01764230-2013-01-09-e19225da2081))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01764230 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-01-09, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct01764230-2013-01-09-e19225da2081`](#source-ctg-observation-nct01764230-2013-01-09-e19225da2081))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01764230-2013-01-09-e19225da2081`](#source-ctg-observation-nct01764230-2013-01-09-e19225da2081))

### Sources

<a id="source-ctg-observation-nct01764230-2013-01-09-e19225da2081"></a>
- **ClinicalTrials.gov record NCT01764230 · retained source version 2013-01-09:e19225da20811ff8cc4e6dc5fe20b4baf040f6aae6a9fc2589ed619f654732ff** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01764230) (`ctg-observation-nct01764230-2013-01-09-e19225da2081`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01764230." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct01764230-triptorelin-v1 SHA-256: 411edfd1f451966190e08470cf674922ad63826d8a64959e755fe93669477007.

---

<a id="clinicaltrials-gov-nct02102646-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT02102646

> PeptideScanner retained ClinicalTrials.gov record NCT02102646 at 2026-11-15T21:49:16.513Z. Its registry update date was 2015-10-28, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct02102646-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-10-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02102646-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct02102646-triptorelin-v1
- Content SHA-256: `5f555a0e546c7c7efeb30386d442db8f289c622fee08720e4136cdbb7ac304a7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02102646 ([`ctg-observation-nct02102646-2015-10-28-1d2c7cf5d467`](#source-ctg-observation-nct02102646-2015-10-28-1d2c7cf5d467))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02102646 at 2026-11-15T21:49:16.513Z. Its registry update date was 2015-10-28, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct02102646-2015-10-28-1d2c7cf5d467`](#source-ctg-observation-nct02102646-2015-10-28-1d2c7cf5d467))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02102646 at 2026-11-15T21:49:16.513Z. Its registry update date was 2015-10-28, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct02102646-2015-10-28-1d2c7cf5d467`](#source-ctg-observation-nct02102646-2015-10-28-1d2c7cf5d467))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02102646-2015-10-28-1d2c7cf5d467`](#source-ctg-observation-nct02102646-2015-10-28-1d2c7cf5d467))

### Sources

<a id="source-ctg-observation-nct02102646-2015-10-28-1d2c7cf5d467"></a>
- **ClinicalTrials.gov record NCT02102646 · retained source version 2015-10-28:1d2c7cf5d467ef86627df1d5b5c8fe843dc2fdaaeb3d90433bb725f0d55153e6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02102646) (`ctg-observation-nct02102646-2015-10-28-1d2c7cf5d467`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02102646." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct02102646-triptorelin-v1 SHA-256: 5f555a0e546c7c7efeb30386d442db8f289c622fee08720e4136cdbb7ac304a7.

---

<a id="clinicaltrials-gov-nct02208986-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT02208986

> PeptideScanner retained ClinicalTrials.gov record NCT02208986 at 2026-11-15T21:49:16.513Z. Its registry update date was 2017-02-06, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct02208986-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-02-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02208986-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct02208986-triptorelin-v1
- Content SHA-256: `e36873de8726300b52336b796684b7c3e28aafb9879da1b0ee5c67b46a64a602`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02208986 ([`ctg-observation-nct02208986-2017-02-06-fd4146bd82fe`](#source-ctg-observation-nct02208986-2017-02-06-fd4146bd82fe))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02208986 at 2026-11-15T21:49:16.513Z. Its registry update date was 2017-02-06, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct02208986-2017-02-06-fd4146bd82fe`](#source-ctg-observation-nct02208986-2017-02-06-fd4146bd82fe))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02208986 at 2026-11-15T21:49:16.513Z. Its registry update date was 2017-02-06, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct02208986-2017-02-06-fd4146bd82fe`](#source-ctg-observation-nct02208986-2017-02-06-fd4146bd82fe))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02208986-2017-02-06-fd4146bd82fe`](#source-ctg-observation-nct02208986-2017-02-06-fd4146bd82fe))

### Sources

<a id="source-ctg-observation-nct02208986-2017-02-06-fd4146bd82fe"></a>
- **ClinicalTrials.gov record NCT02208986 · retained source version 2017-02-06:fd4146bd82fee58ae388ea5d889a71fdea7b045e94f8c20d772f3c6230a20823** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02208986) (`ctg-observation-nct02208986-2017-02-06-fd4146bd82fe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02208986." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct02208986-triptorelin-v1 SHA-256: e36873de8726300b52336b796684b7c3e28aafb9879da1b0ee5c67b46a64a602.

---

<a id="clinicaltrials-gov-nct02238366-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT02238366

> PeptideScanner retained ClinicalTrials.gov record NCT02238366 at 2026-11-15T21:49:16.513Z. Its registry update date was 2019-07-25, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct02238366-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-07-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02238366-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct02238366-triptorelin-v1
- Content SHA-256: `4c0ff239a9a8c1abb08e92e188b15f7f20144ccc248c512f95e47bb370c17e61`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02238366 ([`ctg-observation-nct02238366-2019-07-25-3a4b3b484592`](#source-ctg-observation-nct02238366-2019-07-25-3a4b3b484592))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02238366 at 2026-11-15T21:49:16.513Z. Its registry update date was 2019-07-25, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct02238366-2019-07-25-3a4b3b484592`](#source-ctg-observation-nct02238366-2019-07-25-3a4b3b484592))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02238366 at 2026-11-15T21:49:16.513Z. Its registry update date was 2019-07-25, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct02238366-2019-07-25-3a4b3b484592`](#source-ctg-observation-nct02238366-2019-07-25-3a4b3b484592))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02238366-2019-07-25-3a4b3b484592`](#source-ctg-observation-nct02238366-2019-07-25-3a4b3b484592))

### Sources

<a id="source-ctg-observation-nct02238366-2019-07-25-3a4b3b484592"></a>
- **ClinicalTrials.gov record NCT02238366 · retained source version 2019-07-25:3a4b3b484592284f9d42c32684c92443fe409c45c3d0b1d485c4f6d47e4cba25** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02238366) (`ctg-observation-nct02238366-2019-07-25-3a4b3b484592`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02238366." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct02238366-triptorelin-v1 SHA-256: 4c0ff239a9a8c1abb08e92e188b15f7f20144ccc248c512f95e47bb370c17e61.

---

<a id="clinicaltrials-gov-nct02400801-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT02400801

> PeptideScanner retained ClinicalTrials.gov record NCT02400801 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-07-10, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct02400801-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-07-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02400801-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct02400801-triptorelin-v1
- Content SHA-256: `82b53e3ec7bc0be28b99d6fdf8f961238a4666e9bcdbabc9c74c9cedea809ea2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02400801 ([`ctg-observation-nct02400801-2024-07-10-a238e74c4f25`](#source-ctg-observation-nct02400801-2024-07-10-a238e74c4f25))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02400801 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-07-10, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct02400801-2024-07-10-a238e74c4f25`](#source-ctg-observation-nct02400801-2024-07-10-a238e74c4f25))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02400801 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-07-10, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct02400801-2024-07-10-a238e74c4f25`](#source-ctg-observation-nct02400801-2024-07-10-a238e74c4f25))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02400801-2024-07-10-a238e74c4f25`](#source-ctg-observation-nct02400801-2024-07-10-a238e74c4f25))

### Sources

<a id="source-ctg-observation-nct02400801-2024-07-10-a238e74c4f25"></a>
- **ClinicalTrials.gov record NCT02400801 · retained source version 2024-07-10:a238e74c4f256e33cb18242f9c0b8fdd29177d384f2dd011565dd0b692a4ac2c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02400801) (`ctg-observation-nct02400801-2024-07-10-a238e74c4f25`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02400801." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct02400801-triptorelin-v1 SHA-256: 82b53e3ec7bc0be28b99d6fdf8f961238a4666e9bcdbabc9c74c9cedea809ea2.

---

<a id="clinicaltrials-gov-nct03115307-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT03115307

> PeptideScanner retained ClinicalTrials.gov record NCT03115307 at 2026-11-15T21:49:16.513Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct03115307-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03115307-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct03115307-triptorelin-v1
- Content SHA-256: `84125b54fddd4555cecf27540a7210b9b12044cbba1c784a39ce0b5ad0cd6e67`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03115307 ([`ctg-observation-nct03115307-2020-01-27-f178175d60b7`](#source-ctg-observation-nct03115307-2020-01-27-f178175d60b7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03115307 at 2026-11-15T21:49:16.513Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct03115307-2020-01-27-f178175d60b7`](#source-ctg-observation-nct03115307-2020-01-27-f178175d60b7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03115307 at 2026-11-15T21:49:16.513Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct03115307-2020-01-27-f178175d60b7`](#source-ctg-observation-nct03115307-2020-01-27-f178175d60b7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03115307-2020-01-27-f178175d60b7`](#source-ctg-observation-nct03115307-2020-01-27-f178175d60b7))

### Sources

<a id="source-ctg-observation-nct03115307-2020-01-27-f178175d60b7"></a>
- **ClinicalTrials.gov record NCT03115307 · retained source version 2020-01-27:f178175d60b72c1885b90d8dd7085b9a9f3c37cd075c4c824010d869827b5c20** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03115307) (`ctg-observation-nct03115307-2020-01-27-f178175d60b7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03115307." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct03115307-triptorelin-v1 SHA-256: 84125b54fddd4555cecf27540a7210b9b12044cbba1c784a39ce0b5ad0cd6e67.

---

<a id="clinicaltrials-gov-nct03169166-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT03169166

> PeptideScanner retained ClinicalTrials.gov record NCT03169166 at 2026-11-15T21:49:16.513Z. Its registry update date was 2023-07-20, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct03169166-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03169166-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct03169166-triptorelin-v1
- Content SHA-256: `80bcd171fed1622452bade7932817fff299ec10074cabbd6ff7e29ceb6c0326e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03169166 ([`ctg-observation-nct03169166-2023-07-20-91e68f654eba`](#source-ctg-observation-nct03169166-2023-07-20-91e68f654eba))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03169166 at 2026-11-15T21:49:16.513Z. Its registry update date was 2023-07-20, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct03169166-2023-07-20-91e68f654eba`](#source-ctg-observation-nct03169166-2023-07-20-91e68f654eba))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03169166 at 2026-11-15T21:49:16.513Z. Its registry update date was 2023-07-20, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct03169166-2023-07-20-91e68f654eba`](#source-ctg-observation-nct03169166-2023-07-20-91e68f654eba))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03169166-2023-07-20-91e68f654eba`](#source-ctg-observation-nct03169166-2023-07-20-91e68f654eba))

### Sources

<a id="source-ctg-observation-nct03169166-2023-07-20-91e68f654eba"></a>
- **ClinicalTrials.gov record NCT03169166 · retained source version 2023-07-20:91e68f654eba479531a98c5abd5323b849cb786a52289582cef8172eba3eb7ef** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03169166) (`ctg-observation-nct03169166-2023-07-20-91e68f654eba`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03169166." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct03169166-triptorelin-v1 SHA-256: 80bcd171fed1622452bade7932817fff299ec10074cabbd6ff7e29ceb6c0326e.

---

<a id="clinicaltrials-gov-nct04189900-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT04189900

> PeptideScanner retained ClinicalTrials.gov record NCT04189900 at 2026-11-15T21:49:16.513Z. Its registry update date was 2019-12-11, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct04189900-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-12-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04189900-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct04189900-triptorelin-v1
- Content SHA-256: `6a80cf3022638330a37b9ba44db6218a2e20b5f9a8409314bc107fd1f61e25a0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04189900 ([`ctg-observation-nct04189900-2019-12-11-137b7fbb32c7`](#source-ctg-observation-nct04189900-2019-12-11-137b7fbb32c7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04189900 at 2026-11-15T21:49:16.513Z. Its registry update date was 2019-12-11, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct04189900-2019-12-11-137b7fbb32c7`](#source-ctg-observation-nct04189900-2019-12-11-137b7fbb32c7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04189900 at 2026-11-15T21:49:16.513Z. Its registry update date was 2019-12-11, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct04189900-2019-12-11-137b7fbb32c7`](#source-ctg-observation-nct04189900-2019-12-11-137b7fbb32c7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04189900-2019-12-11-137b7fbb32c7`](#source-ctg-observation-nct04189900-2019-12-11-137b7fbb32c7))

### Sources

<a id="source-ctg-observation-nct04189900-2019-12-11-137b7fbb32c7"></a>
- **ClinicalTrials.gov record NCT04189900 · retained source version 2019-12-11:137b7fbb32c7ca9452ab8b4d1862e35680ba9fde1f2a4d94466576c548f8cfed** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04189900) (`ctg-observation-nct04189900-2019-12-11-137b7fbb32c7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04189900." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct04189900-triptorelin-v1 SHA-256: 6a80cf3022638330a37b9ba44db6218a2e20b5f9a8409314bc107fd1f61e25a0.

---

<a id="clinicaltrials-gov-nct04659551-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT04659551

> PeptideScanner retained ClinicalTrials.gov record NCT04659551 at 2026-11-15T21:49:16.513Z. Its registry update date was 2020-12-09, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct04659551-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-12-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04659551-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct04659551-triptorelin-v1
- Content SHA-256: `f8c77b538992a748ac095c1f48a1af49324cbb8a2392c13e878c9a5b1e90a9a8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04659551 ([`ctg-observation-nct04659551-2020-12-09-8d764479869e`](#source-ctg-observation-nct04659551-2020-12-09-8d764479869e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04659551 at 2026-11-15T21:49:16.513Z. Its registry update date was 2020-12-09, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct04659551-2020-12-09-8d764479869e`](#source-ctg-observation-nct04659551-2020-12-09-8d764479869e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04659551 at 2026-11-15T21:49:16.513Z. Its registry update date was 2020-12-09, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct04659551-2020-12-09-8d764479869e`](#source-ctg-observation-nct04659551-2020-12-09-8d764479869e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04659551-2020-12-09-8d764479869e`](#source-ctg-observation-nct04659551-2020-12-09-8d764479869e))

### Sources

<a id="source-ctg-observation-nct04659551-2020-12-09-8d764479869e"></a>
- **ClinicalTrials.gov record NCT04659551 · retained source version 2020-12-09:8d764479869e417682db0a7f39966daf00e5242d3c55ab8f42cbccccf42e1473** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04659551) (`ctg-observation-nct04659551-2020-12-09-8d764479869e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04659551." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct04659551-triptorelin-v1 SHA-256: f8c77b538992a748ac095c1f48a1af49324cbb8a2392c13e878c9a5b1e90a9a8.

---

<a id="clinicaltrials-gov-nct04846218-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT04846218

> PeptideScanner retained ClinicalTrials.gov record NCT04846218 at 2026-11-15T21:49:16.513Z. Its registry update date was 2021-11-18, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct04846218-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04846218-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct04846218-triptorelin-v1
- Content SHA-256: `38c39dd6e00b9e946118617c536ccf2fa32ea891079856ec3f5faba55a7cc4a8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04846218 ([`ctg-observation-nct04846218-2021-11-18-bd263a8e3d47`](#source-ctg-observation-nct04846218-2021-11-18-bd263a8e3d47))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04846218 at 2026-11-15T21:49:16.513Z. Its registry update date was 2021-11-18, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct04846218-2021-11-18-bd263a8e3d47`](#source-ctg-observation-nct04846218-2021-11-18-bd263a8e3d47))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04846218 at 2026-11-15T21:49:16.513Z. Its registry update date was 2021-11-18, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct04846218-2021-11-18-bd263a8e3d47`](#source-ctg-observation-nct04846218-2021-11-18-bd263a8e3d47))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04846218-2021-11-18-bd263a8e3d47`](#source-ctg-observation-nct04846218-2021-11-18-bd263a8e3d47))

### Sources

<a id="source-ctg-observation-nct04846218-2021-11-18-bd263a8e3d47"></a>
- **ClinicalTrials.gov record NCT04846218 · retained source version 2021-11-18:bd263a8e3d47c6bb953e95a1add1e41a96febd555716cd093e868cb78ced4f0a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04846218) (`ctg-observation-nct04846218-2021-11-18-bd263a8e3d47`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04846218." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct04846218-triptorelin-v1 SHA-256: 38c39dd6e00b9e946118617c536ccf2fa32ea891079856ec3f5faba55a7cc4a8.

---

<a id="clinicaltrials-gov-nct05896566-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT05896566

> PeptideScanner retained ClinicalTrials.gov record NCT05896566 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct05896566-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05896566-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct05896566-triptorelin-v1
- Content SHA-256: `d3d4550f0c0cc019ac301fbb52953133532144d866a8ebb123a536509caed395`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05896566 ([`ctg-observation-nct05896566-2026-02-24-c551d0aff538`](#source-ctg-observation-nct05896566-2026-02-24-c551d0aff538))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05896566 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct05896566-2026-02-24-c551d0aff538`](#source-ctg-observation-nct05896566-2026-02-24-c551d0aff538))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05896566 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct05896566-2026-02-24-c551d0aff538`](#source-ctg-observation-nct05896566-2026-02-24-c551d0aff538))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05896566-2026-02-24-c551d0aff538`](#source-ctg-observation-nct05896566-2026-02-24-c551d0aff538))

### Sources

<a id="source-ctg-observation-nct05896566-2026-02-24-c551d0aff538"></a>
- **ClinicalTrials.gov record NCT05896566 · retained source version 2026-02-24:c551d0aff538779ef2f7908cf0ab269173a78c88af94a68bb8dc7854ff2276df** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05896566) (`ctg-observation-nct05896566-2026-02-24-c551d0aff538`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05896566." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct05896566-triptorelin-v1 SHA-256: d3d4550f0c0cc019ac301fbb52953133532144d866a8ebb123a536509caed395.

---

<a id="clinicaltrials-gov-nct05982093-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT05982093

> PeptideScanner retained ClinicalTrials.gov record NCT05982093 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-04-24, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct05982093-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05982093-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct05982093-triptorelin-v1
- Content SHA-256: `314e3697e078fd25a5e9cb1f89e6029901101c50ea1f8802d8e3e09fa07cfa1d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05982093 ([`ctg-observation-nct05982093-2026-04-24-9061b3ee9dd2`](#source-ctg-observation-nct05982093-2026-04-24-9061b3ee9dd2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05982093 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-04-24, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct05982093-2026-04-24-9061b3ee9dd2`](#source-ctg-observation-nct05982093-2026-04-24-9061b3ee9dd2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05982093 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-04-24, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct05982093-2026-04-24-9061b3ee9dd2`](#source-ctg-observation-nct05982093-2026-04-24-9061b3ee9dd2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05982093-2026-04-24-9061b3ee9dd2`](#source-ctg-observation-nct05982093-2026-04-24-9061b3ee9dd2))

### Sources

<a id="source-ctg-observation-nct05982093-2026-04-24-9061b3ee9dd2"></a>
- **ClinicalTrials.gov record NCT05982093 · retained source version 2026-04-24:9061b3ee9dd2854a9a65f76a8c90fef5edcd079b596bead5606ecd6362a1bcae** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05982093) (`ctg-observation-nct05982093-2026-04-24-9061b3ee9dd2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05982093." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct05982093-triptorelin-v1 SHA-256: 314e3697e078fd25a5e9cb1f89e6029901101c50ea1f8802d8e3e09fa07cfa1d.

---

<a id="clinicaltrials-gov-nct06473259-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT06473259

> PeptideScanner retained ClinicalTrials.gov record NCT06473259 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-06-25, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct06473259-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-06-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06473259-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct06473259-triptorelin-v1
- Content SHA-256: `bb19faf4eb8336939622e15bfb1df359b4eeaa3451a0cc2881ea6a9dbc072c18`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06473259 ([`ctg-observation-nct06473259-2024-06-25-ab61a0647a74`](#source-ctg-observation-nct06473259-2024-06-25-ab61a0647a74))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06473259 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-06-25, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct06473259-2024-06-25-ab61a0647a74`](#source-ctg-observation-nct06473259-2024-06-25-ab61a0647a74))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06473259 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-06-25, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct06473259-2024-06-25-ab61a0647a74`](#source-ctg-observation-nct06473259-2024-06-25-ab61a0647a74))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06473259-2024-06-25-ab61a0647a74`](#source-ctg-observation-nct06473259-2024-06-25-ab61a0647a74))

### Sources

<a id="source-ctg-observation-nct06473259-2024-06-25-ab61a0647a74"></a>
- **ClinicalTrials.gov record NCT06473259 · retained source version 2024-06-25:ab61a0647a7484602a98ee07f51ef9986befc1cfc4e7f79562a5ed5ff42486e3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06473259) (`ctg-observation-nct06473259-2024-06-25-ab61a0647a74`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06473259." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct06473259-triptorelin-v1 SHA-256: bb19faf4eb8336939622e15bfb1df359b4eeaa3451a0cc2881ea6a9dbc072c18.

---

<a id="clinicaltrials-gov-nct06513962-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT06513962

> PeptideScanner retained ClinicalTrials.gov record NCT06513962 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct06513962-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06513962-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct06513962-triptorelin-v1
- Content SHA-256: `7fcff80f8dc809171ac0b4d5b031a1aae1127b33584a6a2edb5a7028f0c8c39d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06513962 ([`ctg-observation-nct06513962-2026-08-31-7fcdfa330a39`](#source-ctg-observation-nct06513962-2026-08-31-7fcdfa330a39))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06513962 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct06513962-2026-08-31-7fcdfa330a39`](#source-ctg-observation-nct06513962-2026-08-31-7fcdfa330a39))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06513962 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct06513962-2026-08-31-7fcdfa330a39`](#source-ctg-observation-nct06513962-2026-08-31-7fcdfa330a39))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06513962-2026-08-31-7fcdfa330a39`](#source-ctg-observation-nct06513962-2026-08-31-7fcdfa330a39))

### Sources

<a id="source-ctg-observation-nct06513962-2026-08-31-7fcdfa330a39"></a>
- **ClinicalTrials.gov record NCT06513962 · retained source version 2026-08-31:7fcdfa330a395eac3bbb201b8f571f89da495b033f4e6d4498ed19fc42e446ae** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06513962) (`ctg-observation-nct06513962-2026-08-31-7fcdfa330a39`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06513962." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct06513962-triptorelin-v1 SHA-256: 7fcff80f8dc809171ac0b4d5b031a1aae1127b33584a6a2edb5a7028f0c8c39d.

---

<a id="clinicaltrials-gov-nct06581679-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT06581679

> PeptideScanner retained ClinicalTrials.gov record NCT06581679 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-09-03, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct06581679-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-09-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06581679-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct06581679-triptorelin-v1
- Content SHA-256: `6f8d3316d430ee50d0c0644ba197818c8b909d88763088a121c7206debdfa0a5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06581679 ([`ctg-observation-nct06581679-2024-09-03-c024048eb1e6`](#source-ctg-observation-nct06581679-2024-09-03-c024048eb1e6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06581679 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-09-03, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct06581679-2024-09-03-c024048eb1e6`](#source-ctg-observation-nct06581679-2024-09-03-c024048eb1e6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06581679 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-09-03, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct06581679-2024-09-03-c024048eb1e6`](#source-ctg-observation-nct06581679-2024-09-03-c024048eb1e6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06581679-2024-09-03-c024048eb1e6`](#source-ctg-observation-nct06581679-2024-09-03-c024048eb1e6))

### Sources

<a id="source-ctg-observation-nct06581679-2024-09-03-c024048eb1e6"></a>
- **ClinicalTrials.gov record NCT06581679 · retained source version 2024-09-03:c024048eb1e69d4d40e0633e7c4ad425bc393c65f61eba2b44ff91c08f332106** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06581679) (`ctg-observation-nct06581679-2024-09-03-c024048eb1e6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06581679." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct06581679-triptorelin-v1 SHA-256: 6f8d3316d430ee50d0c0644ba197818c8b909d88763088a121c7206debdfa0a5.

---

<a id="clinicaltrials-gov-nct07128394-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT07128394

> PeptideScanner retained ClinicalTrials.gov record NCT07128394 at 2026-11-15T21:49:16.513Z. Its registry update date was 2025-08-19, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct07128394-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-08-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07128394-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct07128394-triptorelin-v1
- Content SHA-256: `5af241a3b3b65caaaf6ed0faa1bfca337dde102d08ff475e73fee87af64a56d8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07128394 ([`ctg-observation-nct07128394-2025-08-19-419fefcde432`](#source-ctg-observation-nct07128394-2025-08-19-419fefcde432))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07128394 at 2026-11-15T21:49:16.513Z. Its registry update date was 2025-08-19, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct07128394-2025-08-19-419fefcde432`](#source-ctg-observation-nct07128394-2025-08-19-419fefcde432))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07128394 at 2026-11-15T21:49:16.513Z. Its registry update date was 2025-08-19, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct07128394-2025-08-19-419fefcde432`](#source-ctg-observation-nct07128394-2025-08-19-419fefcde432))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07128394-2025-08-19-419fefcde432`](#source-ctg-observation-nct07128394-2025-08-19-419fefcde432))

### Sources

<a id="source-ctg-observation-nct07128394-2025-08-19-419fefcde432"></a>
- **ClinicalTrials.gov record NCT07128394 · retained source version 2025-08-19:419fefcde4321682fefa013667e5f777d718c80935e7e285b852e99522e48fbb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07128394) (`ctg-observation-nct07128394-2025-08-19-419fefcde432`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07128394." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct07128394-triptorelin-v1 SHA-256: 5af241a3b3b65caaaf6ed0faa1bfca337dde102d08ff475e73fee87af64a56d8.

---

<a id="clinicaltrials-gov-nct07816562-triptorelin-v1"></a>

## ClinicalTrials.gov record NCT07816562

> PeptideScanner retained ClinicalTrials.gov record NCT07816562 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was triptorelin.

- Evidence object: `story:clinicaltrials-gov-nct07816562-triptorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07816562-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct07816562-triptorelin-v1
- Content SHA-256: `21648918d142a617943d4fb3ee1812c76a239117e31dcf39f4c3542289fb5fb6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07816562 ([`ctg-observation-nct07816562-2026-09-11-690df8721b99`](#source-ctg-observation-nct07816562-2026-09-11-690df8721b99))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07816562 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct07816562-2026-09-11-690df8721b99`](#source-ctg-observation-nct07816562-2026-09-11-690df8721b99))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07816562 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was triptorelin. ([`ctg-observation-nct07816562-2026-09-11-690df8721b99`](#source-ctg-observation-nct07816562-2026-09-11-690df8721b99))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07816562-2026-09-11-690df8721b99`](#source-ctg-observation-nct07816562-2026-09-11-690df8721b99))

### Sources

<a id="source-ctg-observation-nct07816562-2026-09-11-690df8721b99"></a>
- **ClinicalTrials.gov record NCT07816562 · retained source version 2026-09-11:690df8721b999809008f1805baadf43b246bc52356eb9f1e15cc28a000bf92ad** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07816562) (`ctg-observation-nct07816562-2026-09-11-690df8721b99`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07816562." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#clinicaltrials-gov-nct07816562-triptorelin-v1 SHA-256: 21648918d142a617943d4fb3ee1812c76a239117e31dcf39f4c3542289fb5fb6.

---

<a id="fda-drugs-nda020715-v1"></a>

## Drugs@FDA application NDA020715

> The official Drugs@FDA dataset lists original submission 1 for NDA 020715 with status AP dated 2000-06-15, and names triptorelin pamoate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020715:v1`
- Evidence domain: Regulatory
- Date in source: 2000-06-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020715/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#fda-drugs-nda020715-v1
- Content SHA-256: `f9d187b5a3881c2671f25c4ff32c09f853597367adf6c9d8e90a128156f4bfbd`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020715 ([`fda-drugs-nda020715-2000-06-15-3c6509748831`](#source-fda-drugs-nda020715-2000-06-15-3c6509748831))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020715 with status AP dated 2000-06-15, and names triptorelin pamoate among the application record's active ingredients. ([`fda-drugs-nda020715-2000-06-15-3c6509748831`](#source-fda-drugs-nda020715-2000-06-15-3c6509748831))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020715 with status AP dated 2000-06-15, and names triptorelin pamoate among the application record's active ingredients. ([`fda-drugs-nda020715-2000-06-15-3c6509748831`](#source-fda-drugs-nda020715-2000-06-15-3c6509748831))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020715-2000-06-15-3c6509748831`](#source-fda-drugs-nda020715-2000-06-15-3c6509748831))

### Sources

<a id="source-fda-drugs-nda020715-2000-06-15-3c6509748831"></a>
- **Drugs@FDA application NDA020715 · original submission status AP · 2000-06-15 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020715%22&limit=1) (`fda-drugs-nda020715-2000-06-15-3c6509748831`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020715." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#fda-drugs-nda020715-v1 SHA-256: f9d187b5a3881c2671f25c4ff32c09f853597367adf6c9d8e90a128156f4bfbd.

---

<a id="fda-drugs-nda021288-v1"></a>

## Drugs@FDA application NDA021288

> The official Drugs@FDA dataset lists original submission 1 for NDA 021288 with status AP dated 2001-06-29, and names triptorelin pamoate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021288:v1`
- Evidence domain: Regulatory
- Date in source: 2001-06-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021288/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#fda-drugs-nda021288-v1
- Content SHA-256: `dd038d19ee4151182782ad51c9249d78dbe7fdbff1b9eaaa88b04680ad07be53`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021288 ([`fda-drugs-nda021288-2001-06-29-f732d7b9b87d`](#source-fda-drugs-nda021288-2001-06-29-f732d7b9b87d))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021288 with status AP dated 2001-06-29, and names triptorelin pamoate among the application record's active ingredients. ([`fda-drugs-nda021288-2001-06-29-f732d7b9b87d`](#source-fda-drugs-nda021288-2001-06-29-f732d7b9b87d))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021288 with status AP dated 2001-06-29, and names triptorelin pamoate among the application record's active ingredients. ([`fda-drugs-nda021288-2001-06-29-f732d7b9b87d`](#source-fda-drugs-nda021288-2001-06-29-f732d7b9b87d))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021288-2001-06-29-f732d7b9b87d`](#source-fda-drugs-nda021288-2001-06-29-f732d7b9b87d))

### Sources

<a id="source-fda-drugs-nda021288-2001-06-29-f732d7b9b87d"></a>
- **Drugs@FDA application NDA021288 · original submission status AP · 2001-06-29 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021288%22&limit=1) (`fda-drugs-nda021288-2001-06-29-f732d7b9b87d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021288." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#fda-drugs-nda021288-v1 SHA-256: dd038d19ee4151182782ad51c9249d78dbe7fdbff1b9eaaa88b04680ad07be53.

---

<a id="fda-drugs-nda022437-v1"></a>

## Drugs@FDA application NDA022437

> The official Drugs@FDA dataset lists original submission 1 for NDA 022437 with status AP dated 2010-03-10, and names triptorelin pamoate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda022437:v1`
- Evidence domain: Regulatory
- Date in source: 2010-03-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda022437/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#fda-drugs-nda022437-v1
- Content SHA-256: `882ed91ed11f5eb55357e01bbddcf35efb1556077cc7685e6989d8b8b3cd66de`

### Claims and source pins

#### Headline

Drugs@FDA application NDA022437 ([`fda-drugs-nda022437-2010-03-10-7f41b522b267`](#source-fda-drugs-nda022437-2010-03-10-7f41b522b267))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 022437 with status AP dated 2010-03-10, and names triptorelin pamoate among the application record's active ingredients. ([`fda-drugs-nda022437-2010-03-10-7f41b522b267`](#source-fda-drugs-nda022437-2010-03-10-7f41b522b267))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 022437 with status AP dated 2010-03-10, and names triptorelin pamoate among the application record's active ingredients. ([`fda-drugs-nda022437-2010-03-10-7f41b522b267`](#source-fda-drugs-nda022437-2010-03-10-7f41b522b267))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda022437-2010-03-10-7f41b522b267`](#source-fda-drugs-nda022437-2010-03-10-7f41b522b267))

### Sources

<a id="source-fda-drugs-nda022437-2010-03-10-7f41b522b267"></a>
- **Drugs@FDA application NDA022437 · original submission status AP · 2010-03-10 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA022437%22&limit=1) (`fda-drugs-nda022437-2010-03-10-7f41b522b267`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA022437." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#fda-drugs-nda022437-v1 SHA-256: 882ed91ed11f5eb55357e01bbddcf35efb1556077cc7685e6989d8b8b3cd66de.

---

<a id="fda-drugs-nda208956-v1"></a>

## Drugs@FDA application NDA208956

> The official Drugs@FDA dataset lists original submission 1 for NDA 208956 with status AP dated 2017-06-29, and names triptorelin pamoate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda208956:v1`
- Evidence domain: Regulatory
- Date in source: 2017-06-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda208956/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#fda-drugs-nda208956-v1
- Content SHA-256: `1af9c914976cc754d7f0f16399e2ba071005e3e22fd2351320c7ee70672bb9c5`

### Claims and source pins

#### Headline

Drugs@FDA application NDA208956 ([`fda-drugs-nda208956-2017-06-29-6617f7c99eda`](#source-fda-drugs-nda208956-2017-06-29-6617f7c99eda))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 208956 with status AP dated 2017-06-29, and names triptorelin pamoate among the application record's active ingredients. ([`fda-drugs-nda208956-2017-06-29-6617f7c99eda`](#source-fda-drugs-nda208956-2017-06-29-6617f7c99eda))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 208956 with status AP dated 2017-06-29, and names triptorelin pamoate among the application record's active ingredients. ([`fda-drugs-nda208956-2017-06-29-6617f7c99eda`](#source-fda-drugs-nda208956-2017-06-29-6617f7c99eda))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda208956-2017-06-29-6617f7c99eda`](#source-fda-drugs-nda208956-2017-06-29-6617f7c99eda))

### Sources

<a id="source-fda-drugs-nda208956-2017-06-29-6617f7c99eda"></a>
- **Drugs@FDA application NDA208956 · original submission status AP · 2017-06-29 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA208956%22&limit=1) (`fda-drugs-nda208956-2017-06-29-6617f7c99eda`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA208956." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#fda-drugs-nda208956-v1 SHA-256: 1af9c914976cc754d7f0f16399e2ba071005e3e22fd2351320c7ee70672bb9c5.

---

<a id="federal-register-2012-25989-v1"></a>

## Federal Register rule 2012-25989

> The Federal Register published rule 2012-25989, attributed to FDA and its parent HHS department, on 2012-10-23. Its official title is “New Animal Drugs; Approvals; Changes of Sponsor; Change of Sponsor's Name; Change of Sponsor's Address; Alfaxalone; Ivermectin and Clorsulon; Narasin; Triptorelin,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin.

- Evidence object: `story:federal-register-2012-25989:v1`
- Evidence domain: Regulatory
- Date in source: 2012-10-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2012-25989/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#federal-register-2012-25989-v1
- Content SHA-256: `aca1e1a3265070b4f9a6392405fdea3747b590d1584ea6d2e9988554540e3874`

### Claims and source pins

#### Headline

Federal Register rule 2012-25989 ([`federal-register-2012-25989-f03c749d186f`](#source-federal-register-2012-25989-f03c749d186f))

#### Summary

The Federal Register published rule 2012-25989, attributed to FDA and its parent HHS department, on 2012-10-23. Its official title is “New Animal Drugs; Approvals; Changes of Sponsor; Change of Sponsor's Name; Change of Sponsor's Address; Alfaxalone; Ivermectin and Clorsulon; Narasin; Triptorelin,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin. ([`federal-register-2012-25989-f03c749d186f`](#source-federal-register-2012-25989-f03c749d186f))

#### Paragraph 1

The Federal Register published rule 2012-25989, attributed to FDA and its parent HHS department, on 2012-10-23. Its official title is “New Animal Drugs; Approvals; Changes of Sponsor; Change of Sponsor's Name; Change of Sponsor's Address; Alfaxalone; Ivermectin and Clorsulon; Narasin; Triptorelin,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin. ([`federal-register-2012-25989-f03c749d186f`](#source-federal-register-2012-25989-f03c749d186f))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2012-25989-f03c749d186f`](#source-federal-register-2012-25989-f03c749d186f))

### Sources

<a id="source-federal-register-2012-25989-f03c749d186f"></a>
- **Federal Register rule 2012-25989 · published 2012-10-23 · New Animal Drugs; Approvals; Changes of Sponsor; Change of Sponsor's Name; Change of Sponsor's Address; Alfaxalone; Ivermectin and Clorsulon; Narasin; Triptorelin** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2012-10-23/pdf/2012-25989.pdf) (`federal-register-2012-25989-f03c749d186f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 2012-25989." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#federal-register-2012-25989-v1 SHA-256: aca1e1a3265070b4f9a6392405fdea3747b590d1584ea6d2e9988554540e3874.

---

<a id="federal-register-2015-11003-v1"></a>

## Federal Register notice 2015-11003

> The Federal Register published notice 2015-11003, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OVUGEL,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin.

- Evidence object: `story:federal-register-2015-11003:v1`
- Evidence domain: Regulatory
- Date in source: 2015-05-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2015-11003/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#federal-register-2015-11003-v1
- Content SHA-256: `0eb6022fdbd94e2cb39fc0d75ff19f8b7a72a34a5c607c68ce8d34253fa5cf76`

### Claims and source pins

#### Headline

Federal Register notice 2015-11003 ([`federal-register-2015-11003-e6d77ae84709`](#source-federal-register-2015-11003-e6d77ae84709))

#### Summary

The Federal Register published notice 2015-11003, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OVUGEL,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin. ([`federal-register-2015-11003-e6d77ae84709`](#source-federal-register-2015-11003-e6d77ae84709))

#### Paragraph 1

The Federal Register published notice 2015-11003, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OVUGEL,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin. ([`federal-register-2015-11003-e6d77ae84709`](#source-federal-register-2015-11003-e6d77ae84709))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2015-11003-e6d77ae84709`](#source-federal-register-2015-11003-e6d77ae84709))

### Sources

<a id="source-federal-register-2015-11003-e6d77ae84709"></a>
- **Federal Register notice 2015-11003 · published 2015-05-07 · Determination of Regulatory Review Period for Purposes of Patent Extension; OVUGEL** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-11003.pdf) (`federal-register-2015-11003-e6d77ae84709`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2015-11003." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#federal-register-2015-11003-v1 SHA-256: 0eb6022fdbd94e2cb39fc0d75ff19f8b7a72a34a5c607c68ce8d34253fa5cf76.

---

<a id="federal-register-2025-01226-v1"></a>

## Federal Register rule 2025-01226

> The Federal Register published rule 2025-01226, attributed to FDA and its parent HHS department, on 2025-01-21. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Change of Sponsor; Change of Sponsor Address,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin.

- Evidence object: `story:federal-register-2025-01226:v1`
- Evidence domain: Regulatory
- Date in source: 2025-01-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2025-01226/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#federal-register-2025-01226-v1
- Content SHA-256: `4d9ae2242e65932925d42637605b432f19df08f926710726e1187395046846de`

### Claims and source pins

#### Headline

Federal Register rule 2025-01226 ([`federal-register-2025-01226-1214c78a32e8`](#source-federal-register-2025-01226-1214c78a32e8))

#### Summary

The Federal Register published rule 2025-01226, attributed to FDA and its parent HHS department, on 2025-01-21. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Change of Sponsor; Change of Sponsor Address,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin. ([`federal-register-2025-01226-1214c78a32e8`](#source-federal-register-2025-01226-1214c78a32e8))

#### Paragraph 1

The Federal Register published rule 2025-01226, attributed to FDA and its parent HHS department, on 2025-01-21. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Change of Sponsor; Change of Sponsor Address,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin. ([`federal-register-2025-01226-1214c78a32e8`](#source-federal-register-2025-01226-1214c78a32e8))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2025-01226-1214c78a32e8`](#source-federal-register-2025-01226-1214c78a32e8))

### Sources

<a id="source-federal-register-2025-01226-1214c78a32e8"></a>
- **Federal Register rule 2025-01226 · published 2025-01-21 · New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Change of Sponsor; Change of Sponsor Address** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2025-01-21/pdf/2025-01226.pdf) (`federal-register-2025-01226-1214c78a32e8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 2025-01226." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#federal-register-2025-01226-v1 SHA-256: 4d9ae2242e65932925d42637605b432f19df08f926710726e1187395046846de.

---

<a id="pubmed-pmid-10099998-triptorelin-v1"></a>

## Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study.

> PubMed lists PMID 10099998 in Human reproduction (Oxford, England) as Clinical Trial, Journal Article, with publication-date metadata of 1999-02 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10099998-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-05-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10099998-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-10099998-triptorelin-v1
- Content SHA-256: `151f64aa062a5adfc968a635fa72c483358c093dc7263ebadaa368a125fe7af7`

### Claims and source pins

#### Headline

Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. ([`pubmed-observation-pmid-10099998-2019-05-13-ecab6df949bf`](#source-pubmed-observation-pmid-10099998-2019-05-13-ecab6df949bf))

#### Summary

PubMed lists PMID 10099998 in Human reproduction (Oxford, England) as Clinical Trial, Journal Article, with publication-date metadata of 1999-02 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10099998-2019-05-13-ecab6df949bf`](#source-pubmed-observation-pmid-10099998-2019-05-13-ecab6df949bf))

#### Paragraph 1

PubMed lists PMID 10099998 in Human reproduction (Oxford, England) as Clinical Trial, Journal Article, with publication-date metadata of 1999-02 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10099998-2019-05-13-ecab6df949bf`](#source-pubmed-observation-pmid-10099998-2019-05-13-ecab6df949bf))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10099998-2019-05-13-ecab6df949bf`](#source-pubmed-observation-pmid-10099998-2019-05-13-ecab6df949bf))

### Sources

<a id="source-pubmed-observation-pmid-10099998-2019-05-13-ecab6df949bf"></a>
- **Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. · retained source version 1:2019-05-13:current:ecab6df949bf1a44c33bf0a83c420642a07249f9e86ffa918512f74416576a5a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10099998/) (`pubmed-observation-pmid-10099998-2019-05-13-ecab6df949bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-10099998-triptorelin-v1 SHA-256: 151f64aa062a5adfc968a635fa72c483358c093dc7263ebadaa368a125fe7af7.

---

<a id="pubmed-pmid-10372696-triptorelin-v1"></a>

## Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in…

> PubMed lists PMID 10372696 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, with publication-date metadata of 1999-06 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10372696-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10372696-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-10372696-triptorelin-v1
- Content SHA-256: `7c4f1ef35b3537d7940b232d81260d15bac3ea751a553e4383eb162a2324555c`

### Claims and source pins

#### Headline

Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in… ([`pubmed-observation-pmid-10372696-2022-03-31-6f8f704476bf`](#source-pubmed-observation-pmid-10372696-2022-03-31-6f8f704476bf))

#### Summary

PubMed lists PMID 10372696 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, with publication-date metadata of 1999-06 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10372696-2022-03-31-6f8f704476bf`](#source-pubmed-observation-pmid-10372696-2022-03-31-6f8f704476bf))

#### Paragraph 1

PubMed lists PMID 10372696 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, with publication-date metadata of 1999-06 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10372696-2022-03-31-6f8f704476bf`](#source-pubmed-observation-pmid-10372696-2022-03-31-6f8f704476bf))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10372696-2022-03-31-6f8f704476bf`](#source-pubmed-observation-pmid-10372696-2022-03-31-6f8f704476bf))

### Sources

<a id="source-pubmed-observation-pmid-10372696-2022-03-31-6f8f704476bf"></a>
- **Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. · retained source version 1:2022-03-31:current:6f8f704476bf17f565a97a18a8ba8ac74c19fc06c92b4007b444e16187c0ad55** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10372696/) (`pubmed-observation-pmid-10372696-2022-03-31-6f8f704476bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in…." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-10372696-triptorelin-v1 SHA-256: 7c4f1ef35b3537d7940b232d81260d15bac3ea751a553e4383eb162a2324555c.

---

<a id="pubmed-pmid-10525370-triptorelin-v1"></a>

## A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study.

> PubMed lists PMID 10525370 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 1999-11 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10525370-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10525370-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-10525370-triptorelin-v1
- Content SHA-256: `ef57ee66689bddf028db468d7c4d81e77b55823b2551d0bbe8cfab826ac279c8`

### Claims and source pins

#### Headline

A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study. ([`pubmed-observation-pmid-10525370-2026-01-28-c68622c3f5d0`](#source-pubmed-observation-pmid-10525370-2026-01-28-c68622c3f5d0))

#### Summary

PubMed lists PMID 10525370 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 1999-11 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10525370-2026-01-28-c68622c3f5d0`](#source-pubmed-observation-pmid-10525370-2026-01-28-c68622c3f5d0))

#### Paragraph 1

PubMed lists PMID 10525370 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 1999-11 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10525370-2026-01-28-c68622c3f5d0`](#source-pubmed-observation-pmid-10525370-2026-01-28-c68622c3f5d0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10525370-2026-01-28-c68622c3f5d0`](#source-pubmed-observation-pmid-10525370-2026-01-28-c68622c3f5d0))

### Sources

<a id="source-pubmed-observation-pmid-10525370-2026-01-28-c68622c3f5d0"></a>
- **A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study. · retained source version 1:2026-01-28:current:c68622c3f5d08319d554c01a5fa7dc35392b2e2522bd2e81752b2e8b59855b85** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10525370/) (`pubmed-observation-pmid-10525370-2026-01-28-c68622c3f5d0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-10525370-triptorelin-v1 SHA-256: ef57ee66689bddf028db468d7c4d81e77b55823b2551d0bbe8cfab826ac279c8.

---

<a id="pubmed-pmid-11430944-triptorelin-v1"></a>

## Estrogen 'add-back' and lipid profile during GnRH agonist (triptorelin) therapy.

> PubMed lists PMID 11430944 in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics as Clinical Trial, Journal Article, with publication-date metadata of 2001-07 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-11430944-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11430944-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-11430944-triptorelin-v1
- Content SHA-256: `c9b0ae3de0d61a95a80cbe8edd8e92d98621e1e340d74c551f1182c7bd0fd73c`

### Claims and source pins

#### Headline

Estrogen 'add-back' and lipid profile during GnRH agonist (triptorelin) therapy. ([`pubmed-observation-pmid-11430944-2019-08-22-5e6a898eb42f`](#source-pubmed-observation-pmid-11430944-2019-08-22-5e6a898eb42f))

#### Summary

PubMed lists PMID 11430944 in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics as Clinical Trial, Journal Article, with publication-date metadata of 2001-07 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11430944-2019-08-22-5e6a898eb42f`](#source-pubmed-observation-pmid-11430944-2019-08-22-5e6a898eb42f))

#### Paragraph 1

PubMed lists PMID 11430944 in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics as Clinical Trial, Journal Article, with publication-date metadata of 2001-07 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11430944-2019-08-22-5e6a898eb42f`](#source-pubmed-observation-pmid-11430944-2019-08-22-5e6a898eb42f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11430944-2019-08-22-5e6a898eb42f`](#source-pubmed-observation-pmid-11430944-2019-08-22-5e6a898eb42f))

### Sources

<a id="source-pubmed-observation-pmid-11430944-2019-08-22-5e6a898eb42f"></a>
- **Estrogen 'add-back' and lipid profile during GnRH agonist (triptorelin) therapy. · retained source version 1:2019-08-22:current:5e6a898eb42f885ed48a7034ef35e6454de24da13e9121ecc6e2e95391549386** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11430944/) (`pubmed-observation-pmid-11430944-2019-08-22-5e6a898eb42f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Estrogen 'add-back' and lipid profile during GnRH agonist (triptorelin) therapy." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-11430944-triptorelin-v1 SHA-256: c9b0ae3de0d61a95a80cbe8edd8e92d98621e1e340d74c551f1182c7bd0fd73c.

---

<a id="pubmed-pmid-11526759-triptorelin-v1"></a>

## \[Decapeptyl (triptorelin) in the treatment of endometriosis genitalis externa\].

> PubMed lists PMID 11526759 in Ginekologia polska as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2001-05 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-11526759-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11526759-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-11526759-triptorelin-v1
- Content SHA-256: `c5bf5d03c81d10a355ecfb14fafd3f6a62631c4a5e4ea046c95ef9837c51b0fc`

### Claims and source pins

#### Headline

\[Decapeptyl (triptorelin) in the treatment of endometriosis genitalis externa\]. ([`pubmed-observation-pmid-11526759-2018-11-30-eec64a6691df`](#source-pubmed-observation-pmid-11526759-2018-11-30-eec64a6691df))

#### Summary

PubMed lists PMID 11526759 in Ginekologia polska as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2001-05 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11526759-2018-11-30-eec64a6691df`](#source-pubmed-observation-pmid-11526759-2018-11-30-eec64a6691df))

#### Paragraph 1

PubMed lists PMID 11526759 in Ginekologia polska as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2001-05 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11526759-2018-11-30-eec64a6691df`](#source-pubmed-observation-pmid-11526759-2018-11-30-eec64a6691df))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11526759-2018-11-30-eec64a6691df`](#source-pubmed-observation-pmid-11526759-2018-11-30-eec64a6691df))

### Sources

<a id="source-pubmed-observation-pmid-11526759-2018-11-30-eec64a6691df"></a>
- **\[Decapeptyl (triptorelin) in the treatment of endometriosis genitalis externa\]. · retained source version 1:2018-11-30:current:eec64a6691df7519fc52573e7c288340a74bbe99a298acf0a347609c48c3c42e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11526759/) (`pubmed-observation-pmid-11526759-2018-11-30-eec64a6691df`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Decapeptyl (triptorelin) in the treatment of endometriosis genitalis externa\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-11526759-triptorelin-v1 SHA-256: c5bf5d03c81d10a355ecfb14fafd3f6a62631c4a5e4ea046c95ef9837c51b0fc.

---

<a id="pubmed-pmid-12092661-triptorelin-v1"></a>

## A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma.

> PubMed lists PMID 12092661 in International urology and nephrology as Clinical Trial, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2001 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12092661-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12092661-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-12092661-triptorelin-v1
- Content SHA-256: `b25edbbba9d4baf0b74355dbe0497ca19d1c4287452f0c569614849d8ad46eac`

### Claims and source pins

#### Headline

A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma. ([`pubmed-observation-pmid-12092661-2026-10-19-9da073f50d79`](#source-pubmed-observation-pmid-12092661-2026-10-19-9da073f50d79))

#### Summary

PubMed lists PMID 12092661 in International urology and nephrology as Clinical Trial, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2001 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12092661-2026-10-19-9da073f50d79`](#source-pubmed-observation-pmid-12092661-2026-10-19-9da073f50d79))

#### Paragraph 1

PubMed lists PMID 12092661 in International urology and nephrology as Clinical Trial, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2001 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12092661-2026-10-19-9da073f50d79`](#source-pubmed-observation-pmid-12092661-2026-10-19-9da073f50d79))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12092661-2026-10-19-9da073f50d79`](#source-pubmed-observation-pmid-12092661-2026-10-19-9da073f50d79))

### Sources

<a id="source-pubmed-observation-pmid-12092661-2026-10-19-9da073f50d79"></a>
- **A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma. · retained source version 1:2026-10-19:current:9da073f50d79e3be28b2c62d3a7ace37f86dcda5442a80e231ac5efc528cb96d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12092661/) (`pubmed-observation-pmid-12092661-2026-10-19-9da073f50d79`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-12092661-triptorelin-v1 SHA-256: b25edbbba9d4baf0b74355dbe0497ca19d1c4287452f0c569614849d8ad46eac.

---

<a id="pubmed-pmid-12147888-triptorelin-v1"></a>

## Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty.

> PubMed lists PMID 12147888 in Indian pediatrics as Clinical Trial, Journal Article, with publication-date metadata of 2002-07 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12147888-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12147888-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-12147888-triptorelin-v1
- Content SHA-256: `0209c439cc04aecc9e5d04e081345661aa8df418aee3db0b956a3d89d3d545b8`

### Claims and source pins

#### Headline

Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty. ([`pubmed-observation-pmid-12147888-2018-11-30-91f1efe414b2`](#source-pubmed-observation-pmid-12147888-2018-11-30-91f1efe414b2))

#### Summary

PubMed lists PMID 12147888 in Indian pediatrics as Clinical Trial, Journal Article, with publication-date metadata of 2002-07 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12147888-2018-11-30-91f1efe414b2`](#source-pubmed-observation-pmid-12147888-2018-11-30-91f1efe414b2))

#### Paragraph 1

PubMed lists PMID 12147888 in Indian pediatrics as Clinical Trial, Journal Article, with publication-date metadata of 2002-07 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12147888-2018-11-30-91f1efe414b2`](#source-pubmed-observation-pmid-12147888-2018-11-30-91f1efe414b2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12147888-2018-11-30-91f1efe414b2`](#source-pubmed-observation-pmid-12147888-2018-11-30-91f1efe414b2))

### Sources

<a id="source-pubmed-observation-pmid-12147888-2018-11-30-91f1efe414b2"></a>
- **Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty. · retained source version 1:2018-11-30:current:91f1efe414b2a1972821fa2a93c5fb3861405a19d61f559cd5ba9bad54542501** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12147888/) (`pubmed-observation-pmid-12147888-2018-11-30-91f1efe414b2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-12147888-triptorelin-v1 SHA-256: 0209c439cc04aecc9e5d04e081345661aa8df418aee3db0b956a3d89d3d545b8.

---

<a id="pubmed-pmid-14967363-triptorelin-v1"></a>

## Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis.

> PubMed lists PMID 14967363 in Fertility and sterility as Clinical Trial, Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, and 2 more PubMed publication types, with publication-date metadata of 2004-02 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14967363-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14967363-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-14967363-triptorelin-v1
- Content SHA-256: `aacc4d3535180164ab3b1ec9671a52d22736aaa31b5831ca3a3e30ef4b8e40b0`

### Claims and source pins

#### Headline

Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis. ([`pubmed-observation-pmid-14967363-2018-11-30-2197976502c4`](#source-pubmed-observation-pmid-14967363-2018-11-30-2197976502c4))

#### Summary

PubMed lists PMID 14967363 in Fertility and sterility as Clinical Trial, Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, and 2 more PubMed publication types, with publication-date metadata of 2004-02 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14967363-2018-11-30-2197976502c4`](#source-pubmed-observation-pmid-14967363-2018-11-30-2197976502c4))

#### Paragraph 1

PubMed lists PMID 14967363 in Fertility and sterility as Clinical Trial, Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, and 2 more PubMed publication types, with publication-date metadata of 2004-02 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14967363-2018-11-30-2197976502c4`](#source-pubmed-observation-pmid-14967363-2018-11-30-2197976502c4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14967363-2018-11-30-2197976502c4`](#source-pubmed-observation-pmid-14967363-2018-11-30-2197976502c4))

### Sources

<a id="source-pubmed-observation-pmid-14967363-2018-11-30-2197976502c4"></a>
- **Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis. · retained source version 1:2018-11-30:current:2197976502c4a30a77d46c312a3e4ce922e89e5011d3f8ec7b58b98d63d49a1a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14967363/) (`pubmed-observation-pmid-14967363-2018-11-30-2197976502c4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-14967363-triptorelin-v1 SHA-256: aacc4d3535180164ab3b1ec9671a52d22736aaa31b5831ca3a3e30ef4b8e40b0.

---

<a id="pubmed-pmid-15816337-triptorelin-v1"></a>

## \[Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after trea…

> PubMed lists PMID 15816337 in Revue medicale de Bruxelles as Clinical Trial, Journal Article, with publication-date metadata of 2005-02 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15816337-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15816337-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-15816337-triptorelin-v1
- Content SHA-256: `4594209da5282098a3afa6df9aca7df3ad41a91d49a9a646e2bf823dbb1efb2a`

### Claims and source pins

#### Headline

\[Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after trea… ([`pubmed-observation-pmid-15816337-2018-12-01-38eb90712ec5`](#source-pubmed-observation-pmid-15816337-2018-12-01-38eb90712ec5))

#### Summary

PubMed lists PMID 15816337 in Revue medicale de Bruxelles as Clinical Trial, Journal Article, with publication-date metadata of 2005-02 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15816337-2018-12-01-38eb90712ec5`](#source-pubmed-observation-pmid-15816337-2018-12-01-38eb90712ec5))

#### Paragraph 1

PubMed lists PMID 15816337 in Revue medicale de Bruxelles as Clinical Trial, Journal Article, with publication-date metadata of 2005-02 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15816337-2018-12-01-38eb90712ec5`](#source-pubmed-observation-pmid-15816337-2018-12-01-38eb90712ec5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15816337-2018-12-01-38eb90712ec5`](#source-pubmed-observation-pmid-15816337-2018-12-01-38eb90712ec5))

### Sources

<a id="source-pubmed-observation-pmid-15816337-2018-12-01-38eb90712ec5"></a>
- **\[Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment\]. · retained source version 1:2018-12-01:current:38eb90712ec5d3371091f1c7f907e353ba8005639b4b7841b12ccc9377bf9979** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15816337/) (`pubmed-observation-pmid-15816337-2018-12-01-38eb90712ec5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after trea…." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-15816337-triptorelin-v1 SHA-256: 4594209da5282098a3afa6df9aca7df3ad41a91d49a9a646e2bf823dbb1efb2a.

---

<a id="pubmed-pmid-15820796-triptorelin-v1"></a>

## Early cessation of triptorelin in in vitro fertilization: a double-blind, randomized study.

> PubMed lists PMID 15820796 in Fertility and sterility as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2005-04 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15820796-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15820796-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-15820796-triptorelin-v1
- Content SHA-256: `568b337082bd83cfc97095bf7a8507e8ec9bfc12845080cda38254747cf74156`

### Claims and source pins

#### Headline

Early cessation of triptorelin in in vitro fertilization: a double-blind, randomized study. ([`pubmed-observation-pmid-15820796-2018-12-01-20c16786a32b`](#source-pubmed-observation-pmid-15820796-2018-12-01-20c16786a32b))

#### Summary

PubMed lists PMID 15820796 in Fertility and sterility as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2005-04 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15820796-2018-12-01-20c16786a32b`](#source-pubmed-observation-pmid-15820796-2018-12-01-20c16786a32b))

#### Paragraph 1

PubMed lists PMID 15820796 in Fertility and sterility as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2005-04 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15820796-2018-12-01-20c16786a32b`](#source-pubmed-observation-pmid-15820796-2018-12-01-20c16786a32b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15820796-2018-12-01-20c16786a32b`](#source-pubmed-observation-pmid-15820796-2018-12-01-20c16786a32b))

### Sources

<a id="source-pubmed-observation-pmid-15820796-2018-12-01-20c16786a32b"></a>
- **Early cessation of triptorelin in in vitro fertilization: a double-blind, randomized study. · retained source version 1:2018-12-01:current:20c16786a32ba8897a9b92a228f4475956c766d971e4b030c3970ff6c9fc9512** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15820796/) (`pubmed-observation-pmid-15820796-2018-12-01-20c16786a32b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Early cessation of triptorelin in in vitro fertilization: a double-blind, randomized study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-15820796-triptorelin-v1 SHA-256: 568b337082bd83cfc97095bf7a8507e8ec9bfc12845080cda38254747cf74156.

---

<a id="pubmed-pmid-15822863-triptorelin-v1"></a>

## \[Pharmacodynamics of triptorelin\].

> PubMed lists PMID 15822863 in La Revue du praticien as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15822863-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15822863-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-15822863-triptorelin-v1
- Content SHA-256: `fa9473bb1c4a025796ed080042eedf1221be64fc0cf2f73bae28cc22fc1aba53`

### Claims and source pins

#### Headline

\[Pharmacodynamics of triptorelin\]. ([`pubmed-observation-pmid-15822863-2018-12-01-101ef19489bc`](#source-pubmed-observation-pmid-15822863-2018-12-01-101ef19489bc))

#### Summary

PubMed lists PMID 15822863 in La Revue du praticien as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15822863-2018-12-01-101ef19489bc`](#source-pubmed-observation-pmid-15822863-2018-12-01-101ef19489bc))

#### Paragraph 1

PubMed lists PMID 15822863 in La Revue du praticien as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15822863-2018-12-01-101ef19489bc`](#source-pubmed-observation-pmid-15822863-2018-12-01-101ef19489bc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15822863-2018-12-01-101ef19489bc`](#source-pubmed-observation-pmid-15822863-2018-12-01-101ef19489bc))

### Sources

<a id="source-pubmed-observation-pmid-15822863-2018-12-01-101ef19489bc"></a>
- **\[Pharmacodynamics of triptorelin\]. · retained source version 1:2018-12-01:current:101ef19489bcb4d91e43953e8b3879d5159faf7cab250022760bb68b8f366b7d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15822863/) (`pubmed-observation-pmid-15822863-2018-12-01-101ef19489bc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Pharmacodynamics of triptorelin\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-15822863-triptorelin-v1 SHA-256: fa9473bb1c4a025796ed080042eedf1221be64fc0cf2f73bae28cc22fc1aba53.

---

<a id="pubmed-pmid-16302716-triptorelin-v1"></a>

## \[Pharmacokinetics and pharmacodynamics of triptorelin\].

> PubMed lists PMID 16302716 in Annales d'urologie as Journal Article, Review, with publication-date metadata of 2005-10 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16302716-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16302716-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-16302716-triptorelin-v1
- Content SHA-256: `a7a247475d7c4dc840263ab6bd1f2b69893653ea19494af679836a437bdc791a`

### Claims and source pins

#### Headline

\[Pharmacokinetics and pharmacodynamics of triptorelin\]. ([`pubmed-observation-pmid-16302716-2019-11-09-2d7bf363b482`](#source-pubmed-observation-pmid-16302716-2019-11-09-2d7bf363b482))

#### Summary

PubMed lists PMID 16302716 in Annales d'urologie as Journal Article, Review, with publication-date metadata of 2005-10 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16302716-2019-11-09-2d7bf363b482`](#source-pubmed-observation-pmid-16302716-2019-11-09-2d7bf363b482))

#### Paragraph 1

PubMed lists PMID 16302716 in Annales d'urologie as Journal Article, Review, with publication-date metadata of 2005-10 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16302716-2019-11-09-2d7bf363b482`](#source-pubmed-observation-pmid-16302716-2019-11-09-2d7bf363b482))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16302716-2019-11-09-2d7bf363b482`](#source-pubmed-observation-pmid-16302716-2019-11-09-2d7bf363b482))

### Sources

<a id="source-pubmed-observation-pmid-16302716-2019-11-09-2d7bf363b482"></a>
- **\[Pharmacokinetics and pharmacodynamics of triptorelin\]. · retained source version 1:2019-11-09:current:2d7bf363b4825254796992d7a87b9a52962c84569ae12520b8adf2c16baf0a7f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16302716/) (`pubmed-observation-pmid-16302716-2019-11-09-2d7bf363b482`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Pharmacokinetics and pharmacodynamics of triptorelin\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-16302716-triptorelin-v1 SHA-256: a7a247475d7c4dc840263ab6bd1f2b69893653ea19494af679836a437bdc791a.

---

<a id="pubmed-pmid-17159461-triptorelin-v1"></a>

## Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.

> PubMed lists PMID 17159461 in International clinical psychopharmacology as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17159461-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17159461-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-17159461-triptorelin-v1
- Content SHA-256: `29e661aea30318deb00a0da5fd8fc8a1ec39beb039d2febb6987fc5dd15bf8b0`

### Claims and source pins

#### Headline

Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin. ([`pubmed-observation-pmid-17159461-2018-12-01-351da762af81`](#source-pubmed-observation-pmid-17159461-2018-12-01-351da762af81))

#### Summary

PubMed lists PMID 17159461 in International clinical psychopharmacology as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17159461-2018-12-01-351da762af81`](#source-pubmed-observation-pmid-17159461-2018-12-01-351da762af81))

#### Paragraph 1

PubMed lists PMID 17159461 in International clinical psychopharmacology as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17159461-2018-12-01-351da762af81`](#source-pubmed-observation-pmid-17159461-2018-12-01-351da762af81))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17159461-2018-12-01-351da762af81`](#source-pubmed-observation-pmid-17159461-2018-12-01-351da762af81))

### Sources

<a id="source-pubmed-observation-pmid-17159461-2018-12-01-351da762af81"></a>
- **Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin. · retained source version 1:2018-12-01:current:351da762af819f7a17c82093950d0b8886ac6622c86460ac80f4e0871557cbc1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17159461/) (`pubmed-observation-pmid-17159461-2018-12-01-351da762af81`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-17159461-triptorelin-v1 SHA-256: 29e661aea30318deb00a0da5fd8fc8a1ec39beb039d2febb6987fc5dd15bf8b0.

---

<a id="pubmed-pmid-17178185-triptorelin-v1"></a>

## A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis.

> PubMed lists PMID 17178185 in European journal of obstetrics, gynecology, and reproductive biology as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2006-12-18 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17178185-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17178185-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-17178185-triptorelin-v1
- Content SHA-256: `1072006a6787265d0c9318962617e570f2dbfd38f9c7a2f83d5089446a725a91`

### Claims and source pins

#### Headline

A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis. ([`pubmed-observation-pmid-17178185-2018-12-01-478b5afff999`](#source-pubmed-observation-pmid-17178185-2018-12-01-478b5afff999))

#### Summary

PubMed lists PMID 17178185 in European journal of obstetrics, gynecology, and reproductive biology as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2006-12-18 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17178185-2018-12-01-478b5afff999`](#source-pubmed-observation-pmid-17178185-2018-12-01-478b5afff999))

#### Paragraph 1

PubMed lists PMID 17178185 in European journal of obstetrics, gynecology, and reproductive biology as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2006-12-18 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17178185-2018-12-01-478b5afff999`](#source-pubmed-observation-pmid-17178185-2018-12-01-478b5afff999))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17178185-2018-12-01-478b5afff999`](#source-pubmed-observation-pmid-17178185-2018-12-01-478b5afff999))

### Sources

<a id="source-pubmed-observation-pmid-17178185-2018-12-01-478b5afff999"></a>
- **A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis. · retained source version 1:2018-12-01:current:478b5afff99951af12d03b2f01f31c6b9f89c0d45ff23328cbe1110a8fb2824f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17178185/) (`pubmed-observation-pmid-17178185-2018-12-01-478b5afff999`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-17178185-triptorelin-v1 SHA-256: 1072006a6787265d0c9318962617e570f2dbfd38f9c7a2f83d5089446a725a91.

---

<a id="pubmed-pmid-17489325-triptorelin-v1"></a>

## \[Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer\].

> PubMed lists PMID 17489325 in Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2007-04 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17489325-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17489325-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-17489325-triptorelin-v1
- Content SHA-256: `3d18f07a3b6f9075efafc8f62e6e8bc12dffcb032c78486b14b258af96d982c2`

### Claims and source pins

#### Headline

\[Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer\]. ([`pubmed-observation-pmid-17489325-2019-11-10-25ba3d0df384`](#source-pubmed-observation-pmid-17489325-2019-11-10-25ba3d0df384))

#### Summary

PubMed lists PMID 17489325 in Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2007-04 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17489325-2019-11-10-25ba3d0df384`](#source-pubmed-observation-pmid-17489325-2019-11-10-25ba3d0df384))

#### Paragraph 1

PubMed lists PMID 17489325 in Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2007-04 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17489325-2019-11-10-25ba3d0df384`](#source-pubmed-observation-pmid-17489325-2019-11-10-25ba3d0df384))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17489325-2019-11-10-25ba3d0df384`](#source-pubmed-observation-pmid-17489325-2019-11-10-25ba3d0df384))

### Sources

<a id="source-pubmed-observation-pmid-17489325-2019-11-10-25ba3d0df384"></a>
- **\[Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer\]. · retained source version 1:2019-11-10:current:25ba3d0df38450ad0bf1e8906816a3798e5e54798f9e7037406a80d3f5ca5278** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17489325/) (`pubmed-observation-pmid-17489325-2019-11-10-25ba3d0df384`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-17489325-triptorelin-v1 SHA-256: 3d18f07a3b6f9075efafc8f62e6e8bc12dffcb032c78486b14b258af96d982c2.

---

<a id="pubmed-pmid-19888782-triptorelin-v1"></a>

## Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.

> PubMed lists PMID 19888782 in Clinical drug investigation as Clinical Trial, Phase III, Journal Article, Multicenter Study, with publication-date metadata of 2009 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19888782-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19888782-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-19888782-triptorelin-v1
- Content SHA-256: `ae422c31d783acc28ae099e256d6b60ebe972de02671a23ceb8f8c9a386ec63f`

### Claims and source pins

#### Headline

Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. ([`pubmed-observation-pmid-19888782-2026-01-28-497f1622e216`](#source-pubmed-observation-pmid-19888782-2026-01-28-497f1622e216))

#### Summary

PubMed lists PMID 19888782 in Clinical drug investigation as Clinical Trial, Phase III, Journal Article, Multicenter Study, with publication-date metadata of 2009 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19888782-2026-01-28-497f1622e216`](#source-pubmed-observation-pmid-19888782-2026-01-28-497f1622e216))

#### Paragraph 1

PubMed lists PMID 19888782 in Clinical drug investigation as Clinical Trial, Phase III, Journal Article, Multicenter Study, with publication-date metadata of 2009 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19888782-2026-01-28-497f1622e216`](#source-pubmed-observation-pmid-19888782-2026-01-28-497f1622e216))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19888782-2026-01-28-497f1622e216`](#source-pubmed-observation-pmid-19888782-2026-01-28-497f1622e216))

### Sources

<a id="source-pubmed-observation-pmid-19888782-2026-01-28-497f1622e216"></a>
- **Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. · retained source version 1:2026-01-28:current:497f1622e2164eb540552f4fa6383b1d6e191db70cc280d2fe8481048b7958f5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19888782/) (`pubmed-observation-pmid-19888782-2026-01-28-497f1622e216`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-19888782-triptorelin-v1 SHA-256: ae422c31d783acc28ae099e256d6b60ebe972de02671a23ceb8f8c9a386ec63f.

---

<a id="pubmed-pmid-20166771-triptorelin-v1"></a>

## Triptorelin embonate (6-month formulation).

> PubMed lists PMID 20166771 in Drugs as Journal Article, Review, with publication-date metadata of 2010-02-12 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20166771-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-07-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20166771-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-20166771-triptorelin-v1
- Content SHA-256: `abf27d634594f7d035aa21d8c0fc436e3f18120c142b48c4e3a908552803c7ae`

### Claims and source pins

#### Headline

Triptorelin embonate (6-month formulation). ([`pubmed-observation-pmid-20166771-2022-07-16-66dcd2ce6aa8`](#source-pubmed-observation-pmid-20166771-2022-07-16-66dcd2ce6aa8))

#### Summary

PubMed lists PMID 20166771 in Drugs as Journal Article, Review, with publication-date metadata of 2010-02-12 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20166771-2022-07-16-66dcd2ce6aa8`](#source-pubmed-observation-pmid-20166771-2022-07-16-66dcd2ce6aa8))

#### Paragraph 1

PubMed lists PMID 20166771 in Drugs as Journal Article, Review, with publication-date metadata of 2010-02-12 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20166771-2022-07-16-66dcd2ce6aa8`](#source-pubmed-observation-pmid-20166771-2022-07-16-66dcd2ce6aa8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20166771-2022-07-16-66dcd2ce6aa8`](#source-pubmed-observation-pmid-20166771-2022-07-16-66dcd2ce6aa8))

### Sources

<a id="source-pubmed-observation-pmid-20166771-2022-07-16-66dcd2ce6aa8"></a>
- **Triptorelin embonate (6-month formulation). · retained source version 1:2022-07-16:current:66dcd2ce6aa8f68ebab6ed9dd28f926e6a81595bc536f0d9d41fa7e00554cf41** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20166771/) (`pubmed-observation-pmid-20166771-2022-07-16-66dcd2ce6aa8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Triptorelin embonate (6-month formulation)." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-20166771-triptorelin-v1 SHA-256: abf27d634594f7d035aa21d8c0fc436e3f18120c142b48c4e3a908552803c7ae.

---

<a id="pubmed-pmid-20969451-triptorelin-v1"></a>

## Triptorelin embonate: a 6-month formulation for prostate cancer.

> PubMed lists PMID 20969451 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2010-10-23 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20969451-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20969451-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-20969451-triptorelin-v1
- Content SHA-256: `d3140aa7dcec84363939a9e3d1e8ed08b5fecbaaad50777550d80b6bfd06aae8`

### Claims and source pins

#### Headline

Triptorelin embonate: a 6-month formulation for prostate cancer. ([`pubmed-observation-pmid-20969451-2018-12-01-54dac415a73e`](#source-pubmed-observation-pmid-20969451-2018-12-01-54dac415a73e))

#### Summary

PubMed lists PMID 20969451 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2010-10-23 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20969451-2018-12-01-54dac415a73e`](#source-pubmed-observation-pmid-20969451-2018-12-01-54dac415a73e))

#### Paragraph 1

PubMed lists PMID 20969451 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2010-10-23 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20969451-2018-12-01-54dac415a73e`](#source-pubmed-observation-pmid-20969451-2018-12-01-54dac415a73e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20969451-2018-12-01-54dac415a73e`](#source-pubmed-observation-pmid-20969451-2018-12-01-54dac415a73e))

### Sources

<a id="source-pubmed-observation-pmid-20969451-2018-12-01-54dac415a73e"></a>
- **Triptorelin embonate: a 6-month formulation for prostate cancer. · retained source version 1:2018-12-01:current:54dac415a73e06627ac565dfe3b2268974067d20923d8ff6ce940376d92dca3d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20969451/) (`pubmed-observation-pmid-20969451-2018-12-01-54dac415a73e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Triptorelin embonate: a 6-month formulation for prostate cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-20969451-triptorelin-v1 SHA-256: d3140aa7dcec84363939a9e3d1e8ed08b5fecbaaad50777550d80b6bfd06aae8.

---

<a id="pubmed-pmid-22231041-triptorelin-v1"></a>

## Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

> PubMed lists PMID 22231041 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2012-01-09 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22231041-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-12-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22231041-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-22231041-triptorelin-v1
- Content SHA-256: `6313909504c6d178d9ea900d81a2d002abc4926759ce9f4d5d2e255dce5b0e32`

### Claims and source pins

#### Headline

Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. ([`pubmed-observation-pmid-22231041-2024-12-19-2bc2c65af9e7`](#source-pubmed-observation-pmid-22231041-2024-12-19-2bc2c65af9e7))

#### Summary

PubMed lists PMID 22231041 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2012-01-09 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22231041-2024-12-19-2bc2c65af9e7`](#source-pubmed-observation-pmid-22231041-2024-12-19-2bc2c65af9e7))

#### Paragraph 1

PubMed lists PMID 22231041 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2012-01-09 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22231041-2024-12-19-2bc2c65af9e7`](#source-pubmed-observation-pmid-22231041-2024-12-19-2bc2c65af9e7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22231041-2024-12-19-2bc2c65af9e7`](#source-pubmed-observation-pmid-22231041-2024-12-19-2bc2c65af9e7))

### Sources

<a id="source-pubmed-observation-pmid-22231041-2024-12-19-2bc2c65af9e7"></a>
- **Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. · retained source version 1:2024-12-19:current:2bc2c65af9e7ade66cda8de0f3c34f0b9f9a36c26282a9ccd7f089339b3d5bce** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22231041/) (`pubmed-observation-pmid-22231041-2024-12-19-2bc2c65af9e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-22231041-triptorelin-v1 SHA-256: 6313909504c6d178d9ea900d81a2d002abc4926759ce9f4d5d2e255dce5b0e32.

---

<a id="pubmed-pmid-23252566-triptorelin-v1"></a>

## Triptorelin in the management of prostate cancer.

> PubMed lists PMID 23252566 in Future oncology (London, England) as Journal Article, Review, with publication-date metadata of 2013-01 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23252566-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23252566-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-23252566-triptorelin-v1
- Content SHA-256: `21482defd48bac57823b3ea0a301ee4523199cac2b5741e78a119690bc35210a`

### Claims and source pins

#### Headline

Triptorelin in the management of prostate cancer. ([`pubmed-observation-pmid-23252566-2018-12-02-f507a7747ec8`](#source-pubmed-observation-pmid-23252566-2018-12-02-f507a7747ec8))

#### Summary

PubMed lists PMID 23252566 in Future oncology (London, England) as Journal Article, Review, with publication-date metadata of 2013-01 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23252566-2018-12-02-f507a7747ec8`](#source-pubmed-observation-pmid-23252566-2018-12-02-f507a7747ec8))

#### Paragraph 1

PubMed lists PMID 23252566 in Future oncology (London, England) as Journal Article, Review, with publication-date metadata of 2013-01 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23252566-2018-12-02-f507a7747ec8`](#source-pubmed-observation-pmid-23252566-2018-12-02-f507a7747ec8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23252566-2018-12-02-f507a7747ec8`](#source-pubmed-observation-pmid-23252566-2018-12-02-f507a7747ec8))

### Sources

<a id="source-pubmed-observation-pmid-23252566-2018-12-02-f507a7747ec8"></a>
- **Triptorelin in the management of prostate cancer. · retained source version 1:2018-12-02:current:f507a7747ec847ac72e3dcf3f8dafda4344786a30ca64f0244e1f764d2890e32** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23252566/) (`pubmed-observation-pmid-23252566-2018-12-02-f507a7747ec8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Triptorelin in the management of prostate cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-23252566-triptorelin-v1 SHA-256: 21482defd48bac57823b3ea0a301ee4523199cac2b5741e78a119690bc35210a.

---

<a id="pubmed-pmid-24832495-triptorelin-v1"></a>

## Triptorelin for the treatment of endometriosis.

> PubMed lists PMID 24832495 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2014-06 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-24832495-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24832495-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-24832495-triptorelin-v1
- Content SHA-256: `49ec4d8e839bb11b85a6190d57503d72e6c3a4b2f75302d88ae3cbef4bd187c9`

### Claims and source pins

#### Headline

Triptorelin for the treatment of endometriosis. ([`pubmed-observation-pmid-24832495-2018-12-02-5f68ce9f6c7d`](#source-pubmed-observation-pmid-24832495-2018-12-02-5f68ce9f6c7d))

#### Summary

PubMed lists PMID 24832495 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2014-06 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24832495-2018-12-02-5f68ce9f6c7d`](#source-pubmed-observation-pmid-24832495-2018-12-02-5f68ce9f6c7d))

#### Paragraph 1

PubMed lists PMID 24832495 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2014-06 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24832495-2018-12-02-5f68ce9f6c7d`](#source-pubmed-observation-pmid-24832495-2018-12-02-5f68ce9f6c7d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24832495-2018-12-02-5f68ce9f6c7d`](#source-pubmed-observation-pmid-24832495-2018-12-02-5f68ce9f6c7d))

### Sources

<a id="source-pubmed-observation-pmid-24832495-2018-12-02-5f68ce9f6c7d"></a>
- **Triptorelin for the treatment of endometriosis. · retained source version 1:2018-12-02:current:5f68ce9f6c7d03d3527549f7befb775f7e67332de565b236c97cfca078db206c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24832495/) (`pubmed-observation-pmid-24832495-2018-12-02-5f68ce9f6c7d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Triptorelin for the treatment of endometriosis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-24832495-triptorelin-v1 SHA-256: 49ec4d8e839bb11b85a6190d57503d72e6c3a4b2f75302d88ae3cbef4bd187c9.

---

<a id="pubmed-pmid-25990480-triptorelin-v1"></a>

## Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.

> PubMed lists PMID 25990480 in Archives of gynecology and obstetrics as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 2015-05-20 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25990480-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25990480-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-25990480-triptorelin-v1
- Content SHA-256: `465a07c83d33228b0adc61456aafc576d43aacfb6cdec6d2fab6ac38b671c57a`

### Claims and source pins

#### Headline

Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. ([`pubmed-observation-pmid-25990480-2026-11-09-97f2e6f6a540`](#source-pubmed-observation-pmid-25990480-2026-11-09-97f2e6f6a540))

#### Summary

PubMed lists PMID 25990480 in Archives of gynecology and obstetrics as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 2015-05-20 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25990480-2026-11-09-97f2e6f6a540`](#source-pubmed-observation-pmid-25990480-2026-11-09-97f2e6f6a540))

#### Paragraph 1

PubMed lists PMID 25990480 in Archives of gynecology and obstetrics as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 2015-05-20 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25990480-2026-11-09-97f2e6f6a540`](#source-pubmed-observation-pmid-25990480-2026-11-09-97f2e6f6a540))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25990480-2026-11-09-97f2e6f6a540`](#source-pubmed-observation-pmid-25990480-2026-11-09-97f2e6f6a540))

### Sources

<a id="source-pubmed-observation-pmid-25990480-2026-11-09-97f2e6f6a540"></a>
- **Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. · retained source version 1:2026-11-09:current:97f2e6f6a54057af8dfe967a28a701d17cfcb659ecac97b032fbbf18fab83b9a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25990480/) (`pubmed-observation-pmid-25990480-2026-11-09-97f2e6f6a540`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-25990480-triptorelin-v1 SHA-256: 465a07c83d33228b0adc61456aafc576d43aacfb6cdec6d2fab6ac38b671c57a.

---

<a id="pubmed-pmid-27246172-triptorelin-v1"></a>

## An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.

> PubMed lists PMID 27246172 in Advances in therapy as Journal Article, Review, with publication-date metadata of 2016-05-31 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27246172-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-08-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27246172-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-27246172-triptorelin-v1
- Content SHA-256: `2492f7c838719a926069642dc01646f5e964987880aba65be2a19bccd157f915`

### Claims and source pins

#### Headline

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer. ([`pubmed-observation-pmid-27246172-2024-08-08-403f91c18021`](#source-pubmed-observation-pmid-27246172-2024-08-08-403f91c18021))

#### Summary

PubMed lists PMID 27246172 in Advances in therapy as Journal Article, Review, with publication-date metadata of 2016-05-31 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27246172-2024-08-08-403f91c18021`](#source-pubmed-observation-pmid-27246172-2024-08-08-403f91c18021))

#### Paragraph 1

PubMed lists PMID 27246172 in Advances in therapy as Journal Article, Review, with publication-date metadata of 2016-05-31 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27246172-2024-08-08-403f91c18021`](#source-pubmed-observation-pmid-27246172-2024-08-08-403f91c18021))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27246172-2024-08-08-403f91c18021`](#source-pubmed-observation-pmid-27246172-2024-08-08-403f91c18021))

### Sources

<a id="source-pubmed-observation-pmid-27246172-2024-08-08-403f91c18021"></a>
- **An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer. · retained source version 1:2024-08-08:current:403f91c18021531331023bae40421c65028b041fad6dcf39b62152da94b66310** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27246172/) (`pubmed-observation-pmid-27246172-2024-08-08-403f91c18021`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-27246172-triptorelin-v1 SHA-256: 2492f7c838719a926069642dc01646f5e964987880aba65be2a19bccd157f915.

---

<a id="pubmed-pmid-29177573-triptorelin-v1"></a>

## Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.

> PubMed lists PMID 29177573 in Drugs as Journal Article, Review, with publication-date metadata of 2017-12 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29177573-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29177573-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-29177573-triptorelin-v1
- Content SHA-256: `996294d76d4bffa4494a2a11d518b7a69c354f49cc79508a181034dc34b788a0`

### Claims and source pins

#### Headline

Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer. ([`pubmed-observation-pmid-29177573-2026-01-27-50d8a9a3c912`](#source-pubmed-observation-pmid-29177573-2026-01-27-50d8a9a3c912))

#### Summary

PubMed lists PMID 29177573 in Drugs as Journal Article, Review, with publication-date metadata of 2017-12 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29177573-2026-01-27-50d8a9a3c912`](#source-pubmed-observation-pmid-29177573-2026-01-27-50d8a9a3c912))

#### Paragraph 1

PubMed lists PMID 29177573 in Drugs as Journal Article, Review, with publication-date metadata of 2017-12 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29177573-2026-01-27-50d8a9a3c912`](#source-pubmed-observation-pmid-29177573-2026-01-27-50d8a9a3c912))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29177573-2026-01-27-50d8a9a3c912`](#source-pubmed-observation-pmid-29177573-2026-01-27-50d8a9a3c912))

### Sources

<a id="source-pubmed-observation-pmid-29177573-2026-01-27-50d8a9a3c912"></a>
- **Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer. · retained source version 1:2026-01-27:current:50d8a9a3c9128807e04804c8694e156899610b5c4104940561175a6597ebc51a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29177573/) (`pubmed-observation-pmid-29177573-2026-01-27-50d8a9a3c912`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-29177573-triptorelin-v1 SHA-256: 996294d76d4bffa4494a2a11d518b7a69c354f49cc79508a181034dc34b788a0.

---

<a id="pubmed-pmid-29551913-triptorelin-v1"></a>

## Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer.

> PubMed lists PMID 29551913 in Breast cancer (Dove Medical Press) as Journal Article, Review, with publication-date metadata of 2018-03-06 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29551913-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29551913-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-29551913-triptorelin-v1
- Content SHA-256: `8b2edc6a973a8a3ec94b25f46b1a9f86fab3a19e69b21027217372020ea8798b`

### Claims and source pins

#### Headline

Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer. ([`pubmed-observation-pmid-29551913-2024-03-14-c9c9e7dbdbe0`](#source-pubmed-observation-pmid-29551913-2024-03-14-c9c9e7dbdbe0))

#### Summary

PubMed lists PMID 29551913 in Breast cancer (Dove Medical Press) as Journal Article, Review, with publication-date metadata of 2018-03-06 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29551913-2024-03-14-c9c9e7dbdbe0`](#source-pubmed-observation-pmid-29551913-2024-03-14-c9c9e7dbdbe0))

#### Paragraph 1

PubMed lists PMID 29551913 in Breast cancer (Dove Medical Press) as Journal Article, Review, with publication-date metadata of 2018-03-06 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29551913-2024-03-14-c9c9e7dbdbe0`](#source-pubmed-observation-pmid-29551913-2024-03-14-c9c9e7dbdbe0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29551913-2024-03-14-c9c9e7dbdbe0`](#source-pubmed-observation-pmid-29551913-2024-03-14-c9c9e7dbdbe0))

### Sources

<a id="source-pubmed-observation-pmid-29551913-2024-03-14-c9c9e7dbdbe0"></a>
- **Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer. · retained source version 1:2024-03-14:current:c9c9e7dbdbe0679cb79fec9fa9690e1b66765dd069b11078e572c8cd70da286b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29551913/) (`pubmed-observation-pmid-29551913-2024-03-14-c9c9e7dbdbe0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-29551913-triptorelin-v1 SHA-256: 8b2edc6a973a8a3ec94b25f46b1a9f86fab3a19e69b21027217372020ea8798b.

---

<a id="pubmed-pmid-29957076-triptorelin-v1"></a>

## Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.

> PubMed lists PMID 29957076 in Expert review of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2018-07-26 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29957076-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-02-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29957076-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-29957076-triptorelin-v1
- Content SHA-256: `2d6a6c72e4be70ec75431a4dea47e2323bd543ef296dd9b2aa8f1b9801cc0b77`

### Claims and source pins

#### Headline

Triptorelin depot for the treatment of children 2 years and older with central precocious puberty. ([`pubmed-observation-pmid-29957076-2019-02-21-da00b0d382a2`](#source-pubmed-observation-pmid-29957076-2019-02-21-da00b0d382a2))

#### Summary

PubMed lists PMID 29957076 in Expert review of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2018-07-26 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29957076-2019-02-21-da00b0d382a2`](#source-pubmed-observation-pmid-29957076-2019-02-21-da00b0d382a2))

#### Paragraph 1

PubMed lists PMID 29957076 in Expert review of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2018-07-26 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29957076-2019-02-21-da00b0d382a2`](#source-pubmed-observation-pmid-29957076-2019-02-21-da00b0d382a2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29957076-2019-02-21-da00b0d382a2`](#source-pubmed-observation-pmid-29957076-2019-02-21-da00b0d382a2))

### Sources

<a id="source-pubmed-observation-pmid-29957076-2019-02-21-da00b0d382a2"></a>
- **Triptorelin depot for the treatment of children 2 years and older with central precocious puberty. · retained source version 1:2019-02-21:current:da00b0d382a25f050c3bc5b9449557cd1051e6076cf478ad8c4d6bec1d3b1ff4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29957076/) (`pubmed-observation-pmid-29957076-2019-02-21-da00b0d382a2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Triptorelin depot for the treatment of children 2 years and older with central precocious puberty." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-29957076-triptorelin-v1 SHA-256: 2d6a6c72e4be70ec75431a4dea47e2323bd543ef296dd9b2aa8f1b9801cc0b77.

---

<a id="pubmed-pmid-40109078-triptorelin-v1"></a>

## Adolescent Gender Dysphoria in Italy: Reflections on Triptorelin, Consent, and Care.

> PubMed lists PMID 40109078 in La Clinica terapeutica as Journal Article, Review, with publication-date metadata of 2025 Mar-Apr (source-text precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40109078-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-05-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40109078-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-40109078-triptorelin-v1
- Content SHA-256: `b03239b5125e19a1d6df42fc0b3a7d737cbb922dfec0388c6508129c8704b29a`

### Claims and source pins

#### Headline

Adolescent Gender Dysphoria in Italy: Reflections on Triptorelin, Consent, and Care. ([`pubmed-observation-pmid-40109078-2025-05-14-5094f17084d5`](#source-pubmed-observation-pmid-40109078-2025-05-14-5094f17084d5))

#### Summary

PubMed lists PMID 40109078 in La Clinica terapeutica as Journal Article, Review, with publication-date metadata of 2025 Mar-Apr (source-text precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40109078-2025-05-14-5094f17084d5`](#source-pubmed-observation-pmid-40109078-2025-05-14-5094f17084d5))

#### Paragraph 1

PubMed lists PMID 40109078 in La Clinica terapeutica as Journal Article, Review, with publication-date metadata of 2025 Mar-Apr (source-text precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40109078-2025-05-14-5094f17084d5`](#source-pubmed-observation-pmid-40109078-2025-05-14-5094f17084d5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40109078-2025-05-14-5094f17084d5`](#source-pubmed-observation-pmid-40109078-2025-05-14-5094f17084d5))

### Sources

<a id="source-pubmed-observation-pmid-40109078-2025-05-14-5094f17084d5"></a>
- **Adolescent Gender Dysphoria in Italy: Reflections on Triptorelin, Consent, and Care. · retained source version 1:2025-05-14:current:5094f17084d58a6681c629412867876fb4ee0b58e8e5e3f8bc8694d1cf4141eb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40109078/) (`pubmed-observation-pmid-40109078-2025-05-14-5094f17084d5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Adolescent Gender Dysphoria in Italy: Reflections on Triptorelin, Consent, and Care." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-40109078-triptorelin-v1 SHA-256: b03239b5125e19a1d6df42fc0b3a7d737cbb922dfec0388c6508129c8704b29a.

---

<a id="pubmed-pmid-7781864-triptorelin-v1"></a>

## A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis.

> PubMed lists PMID 7781864 in European journal of obstetrics, gynecology, and reproductive biology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-03 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-7781864-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7781864-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-7781864-triptorelin-v1
- Content SHA-256: `10f8aeda7cdb141d1454cc5a04de25bc9a2f7513405754ef7b99c7d856aa81d9`

### Claims and source pins

#### Headline

A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. ([`pubmed-observation-pmid-7781864-2019-08-16-2200be946737`](#source-pubmed-observation-pmid-7781864-2019-08-16-2200be946737))

#### Summary

PubMed lists PMID 7781864 in European journal of obstetrics, gynecology, and reproductive biology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-03 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7781864-2019-08-16-2200be946737`](#source-pubmed-observation-pmid-7781864-2019-08-16-2200be946737))

#### Paragraph 1

PubMed lists PMID 7781864 in European journal of obstetrics, gynecology, and reproductive biology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-03 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7781864-2019-08-16-2200be946737`](#source-pubmed-observation-pmid-7781864-2019-08-16-2200be946737))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7781864-2019-08-16-2200be946737`](#source-pubmed-observation-pmid-7781864-2019-08-16-2200be946737))

### Sources

<a id="source-pubmed-observation-pmid-7781864-2019-08-16-2200be946737"></a>
- **A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. · retained source version 1:2019-08-16:current:2200be946737b22faca30d7dc92b488543ddff4ecc7449158c39c1e2c6c8fcae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7781864/) (`pubmed-observation-pmid-7781864-2019-08-16-2200be946737`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-7781864-triptorelin-v1 SHA-256: 10f8aeda7cdb141d1454cc5a04de25bc9a2f7513405754ef7b99c7d856aa81d9.

---

<a id="pubmed-pmid-8839551-triptorelin-v1"></a>

## Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapept…

> PubMed lists PMID 8839551 in Cancer as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1996-10-01 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8839551-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8839551-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-8839551-triptorelin-v1
- Content SHA-256: `82eea9203ecccb4bcb8fdd12a1a7b7934255b3768c141bfcd8dd99b2c74b1053`

### Claims and source pins

#### Headline

Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapept… ([`pubmed-observation-pmid-8839551-2018-11-30-8d7cf5cfcd94`](#source-pubmed-observation-pmid-8839551-2018-11-30-8d7cf5cfcd94))

#### Summary

PubMed lists PMID 8839551 in Cancer as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1996-10-01 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8839551-2018-11-30-8d7cf5cfcd94`](#source-pubmed-observation-pmid-8839551-2018-11-30-8d7cf5cfcd94))

#### Paragraph 1

PubMed lists PMID 8839551 in Cancer as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1996-10-01 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8839551-2018-11-30-8d7cf5cfcd94`](#source-pubmed-observation-pmid-8839551-2018-11-30-8d7cf5cfcd94))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8839551-2018-11-30-8d7cf5cfcd94`](#source-pubmed-observation-pmid-8839551-2018-11-30-8d7cf5cfcd94))

### Sources

<a id="source-pubmed-observation-pmid-8839551-2018-11-30-8d7cf5cfcd94"></a>
- **Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. · retained source version 1:2018-11-30:current:8d7cf5cfcd948a6556170af0cf9a2b20840079269235c2a6dbc9fc2db24c84c3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8839551/) (`pubmed-observation-pmid-8839551-2018-11-30-8d7cf5cfcd94`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapept…." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-8839551-triptorelin-v1 SHA-256: 82eea9203ecccb4bcb8fdd12a1a7b7934255b3768c141bfcd8dd99b2c74b1053.

---

<a id="pubmed-pmid-8889631-triptorelin-v1"></a>

## Long-acting triptorelin for the treatment of endometriosis.

> PubMed lists PMID 8889631 in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics as Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 1996-09 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8889631-triptorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8889631-triptorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-8889631-triptorelin-v1
- Content SHA-256: `b1c1fe4f8da2eaf25d44b6f827156c0bba615e4dd38c131884092c2ec2912b11`

### Claims and source pins

#### Headline

Long-acting triptorelin for the treatment of endometriosis. ([`pubmed-observation-pmid-8889631-2019-08-22-be0026a8dcbf`](#source-pubmed-observation-pmid-8889631-2019-08-22-be0026a8dcbf))

#### Summary

PubMed lists PMID 8889631 in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics as Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 1996-09 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8889631-2019-08-22-be0026a8dcbf`](#source-pubmed-observation-pmid-8889631-2019-08-22-be0026a8dcbf))

#### Paragraph 1

PubMed lists PMID 8889631 in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics as Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 1996-09 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8889631-2019-08-22-be0026a8dcbf`](#source-pubmed-observation-pmid-8889631-2019-08-22-be0026a8dcbf))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8889631-2019-08-22-be0026a8dcbf`](#source-pubmed-observation-pmid-8889631-2019-08-22-be0026a8dcbf))

### Sources

<a id="source-pubmed-observation-pmid-8889631-2019-08-22-be0026a8dcbf"></a>
- **Long-acting triptorelin for the treatment of endometriosis. · retained source version 1:2019-08-22:current:be0026a8dcbf98b7f2a620756388796307c1d8172990e98e346089e74bbf449b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8889631/) (`pubmed-observation-pmid-8889631-2019-08-22-be0026a8dcbf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Long-acting triptorelin for the treatment of endometriosis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/triptorelin.json#pubmed-pmid-8889631-triptorelin-v1 SHA-256: b1c1fe4f8da2eaf25d44b6f827156c0bba615e4dd38c131884092c2ec2912b11.

